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Abstract
The quantity of marijuana use, the length of time it was used, and the age of initiation of
the drug are at the core of the discussions about the potential health effects of marijuana
use on the liver. Results of recent studies regarding how the drug affects human health
have resulted in a number of conflicting conclusions. Nevertheless, based on these
findings, marijuana users are being denied liver transplants. The objective of this study
was to identify predictors of the health effects of marijuana on the liver and provide
guidance in the care management of marijuana users. To address the inconsistencies in
the research findings, this study was designed to investigate possible associations
between the quantity of marijuana use, the duration of use, and the age of initiation as
they relate changes in liver enzymes. Data from a random sample of 702 participants
obtained from the National Health and Nutrition Examination Survey were analyzed in a
least square linear regression model. The study found that the quantity of marijuana use
has a significant effect on the serum total bilirubin (TB) level with an apparent
detrimental effect on the serum level of TB, R2 = .106, F(3, 19) = 4.859, p < .05, 95% CI
[-.896, -.175]. The duration of use significantly affects the serum level of alkaline
phosphatase, R2 =.074, F(4, 18) = 4.661, p < .05, 95% CI [.00, .004] and total protein, R2
= .077 F(4, 18) = 3.401, p < .05, 95% CI [-.013, .000]. The age of initiation failed to have
a significant health effect on any liver enzymes. This study has the potential to improve
care management for marijuana users by helping to accelerate the diagnosis process and
by improving the policy of liver transplant denial for marijuana users.
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Chapter 1: Introduction to the Study
In 2013, the National Institute of Drug Abuse (NIDA, 2015) reported a significant
increase in the number of people who were using illicit drugs, which was primarily
associated with the increase in marijuana use due to the new laws that decriminalized the
drug (Maier, Mannes, & Koppenhofer, 2017). Drinking alcohol, smoking tobacco, and
the use of cocaine decreased over the same time period (NIDA, 2015), while the rise in
marijuana consumption resulted in an increase in cannabis-related emergency department
visits (Zhu & Wu, 2016). Results of recent studies regarding how the drug affects human
health have resulted in a number of conflicting conclusions. Some studies found a
significant therapeutic effect of the drug on human health, including a positive effect on
the liver, whereas other research warned of marijuana’s adverse health effects (Adejumo
et al., 2017, Volkow et al., 2014). In the medical field, many questions related to the
actual impact of the drug on different organs of the human body, the impact of the drug
on less frequent users, and the effect of the age of initiation and method of consumption
of the drug remain unanswered (Sznitman & Room, 2018).
In recent years, more studies related to marijuana use have emerged (Maier,
Mannes, & Koppenhofer, 2017). Researchers have begun to investigate the risk factors
associated with marijuana and how it affects different human organs including the liver
(Gudsoorkar & Perez Jr., 2015; Kazory & Aiyer, 2013). Although many findings are still
in their early stages, they appear to point in many different directions, including reports
of positive and negative health effects, as well as no significant health effect (Adejumo et
al., 2017; T. Liu et al., 2014; Terry-McElrath et al., 2017). It is important to note that
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several of these studies were conducted on groups of individuals with preexisting liver
conditions, which has the potential to be a source of bias in the findings. In more than
half of these studies, researchers did not consider the age of initiation of cannabis use, the
duration of cannabis use, the quantity of cannabis use, or the method of consumption in
their analysis (Sznitman & Room, 2018). The few studies conducted with healthy
participants failed to distinguish marijuana users from those who were using or abusing
other substances. For instance, several studies reported difficulties in isolating those
individuals who only use cannabis, which has the potential to reduce the sample size and
can negatively impact and skew study results (Quraishi, Jain, Chatterjee, & Verma,
2013). In addition, when evaluating the effect of marijuana on the liver, most studies
failed to consider the difference in age, gender, and race. These unique sociodemographic
factors are potentially important and may affect the results of these studies.
In 2015, more than 11 million Americans reportedly consumed marijuana (NIDA,
2015). The prevalence of marijuana use more than doubled from 2001-2002 to 20122013, which coincided with an increase in the number of cannabis-related emergency
department visits and marijuana-related admissions in hospitals and residential service
treatments (Substance Abuse and Mental Health Services Administration [SAMHSA],
2014). Interestingly, clear evidence of adverse health effects of marijuana use on the liver
was inconsistent. Researchers then began questioning why liver transplants were being
denied to marijuana users and whether marijuana should be classified as a Schedule I
drug. More studies are essential to fully understanding the actual effects of marijuana on
the liver.
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In the laboratory, the health of the liver is assessed by identifying the serum levels
of liver function parameters such as the serum level of alanine aminotransferase (ALT),
aspartate aminotransferase (AST), albumin (ALB), alkaline phosphate (ALP), total
bilirubin (TB), total protein (TP) and the gamma-glutamyl transpeptidase (GGT)
(Fumeaux, Scarpelli, Tettamanti, & Palmiere, 2018). These parameters are indicative of
different functions of the liver and help to assess the health condition of the liver. Hence,
the scope of this study was to analyze how marijuana affects them individually, which is
valuable in the identification of specific effect of the drug on a healthy liver.
Accordingly, in this study, I analyzed the predictors of the health effects of
marijuana on the liver function in different categories of users and evaluated whether the
age of initiation, the length of time marijuana was used, and the amount of marijuana
smoked daily have a significant effect on hepatic function.
Background
The core issues associated with the health effects of marijuana use on the liver
have been found to be related to the user’s age, the age of initiation, the amount of
marijuana smoked, the method of consumption and the preexisting condition of the
smokers (Sznitman & Room, 2018).
Age is a risk factor for many chronic diseases including liver diseases (H. Kim et
al., 2015). Previous research has indicated that younger individuals who use marijuana
are less at risk of developing nonalcoholic fatty liver disease (NAFLD) than older
individuals are (D. Kim et al., 2017). The age-specific onset of marijuana use has varied
throughout history. The percentage of adolescents who tried marijuana before the age of
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13 years increased between 1991 and 1999, but a steady decrease has been observed from
1999 to 2015 (Youth Risk Behavior Surveillance System (YRBSS, 2017). For example,
after using marijuana for more than 30.5 months with an average age of onset of 21.8
years, 34 patients presented no abnormal liver function tests (Kotan et al.,2017). By
contrast, at the age of onset of 15.31 years with 9.53 years of smoking marijuana, 51% of
cannabis dependent patients displayed abnormal liver patterns (Quraishi et al.,2013).
These findings suggest that the duration and the amount of marijuana were critical factors
in determining the detrimental health effects of the drug on the liver. The conclusions
from the above findings were different from other findings that suggested marijuana use
has a therapeutic effect on NAFLD and the severity of hepatitis C virus (HCV) infection
(Adejumo et al., 2018; D. Kim et al., 2017). This contradictory conclusion suggested that
the more marijuana is used and the longer it is used, the more positive effect it has on the
NAFLD and HCV-infected patients. Terry-McElrath et al. (2017) and Quraishi et al.
(2013) also found that the duration of marijuana use is a factor that should be taken into
consideration when analyzing the health effects of marijuana. Terry-McElrath et al.
(2017) associated increased risk of adverse health effects of 50-year-old marijuana users
with moderate to heavy long-term use of marijuana. In addition, Quraishi et al. (2013)
linked the long-term use of marijuana to abnormal liver patterns. The quantity of
marijuana used has also been considered in several studies that evaluated the impact of
marijuana on the liver. Adejumo et al. (2017) suggested that heavy cannabis use
represents a positive contributing factor on the prevalence of NAFLD, whereas TerryMcElrath et al. (2017) concluded that the intensity of marijuana smoked is a strong
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predictor of negative health effects for 50-years old users. Unlike previous studies, T. Liu
et al. (2014) found no significant difference in the health of the liver of 21 patients
infected with HCV who used marijuana compared to HCV-infected nonusers.
Several previous studies have assessed the impact of marijuana on specific liver
enzymes and found conflicting results. Mohamed et al. (2015) concluded that chronic
marijuana use was associated with the hepatic enzymatic alteration. Several other studies
have reported results that indicated the detrimental health effect associated with
marijuana on liver enzymes, including ALT, AST, ALP, TB, ALB, TP, and GGT.
(Mohamed et al., 2015; Quraishi et al., 2013; Wani, Khan, & Singh, 2017). In contrast to
the findings of the above authors, some studies have suggested that marijuana improves
the activity of the liver enzymes (Adejumo et al., 2018; Kim et al., 2017) while another
research group found no significant health impact of the drug on hepatic function (Kotan
et al., 2017; Muniyappa et al., 2013; Rahmayanti et al., 2017).
Problem Statement
Marijuana is the most common illicit drug used in the U.S. (NIDA, 2015).
Concerns about its use are reportedly associated with its adverse cognitive effect
(Mandelbaum & de la Monte, 2017) and its likelihood to cause adverse cardiovascular
events (Thomas, Kloner, & Rezkalla, 2014). With the recent change in social attitudes
toward the use of marijuana and its continued decriminalization (Maier et al., 2017), there
has been an increase in interest related to risk factors associated with use of the drug and
how it affects several organs in the human body (Gudsoorkar & Perez Jr., 2015; Kazory
& Aiyer, 2013). Predictors of the health effects of alcohol and tobacco on the liver are
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well documented (Liu et al., 2017). However, except for a single study published in
Brazil in 2004 (Borini, Guimarães, & Borini, 2004) that attempted to evaluate the
predictors and health effects of marijuana use on the liver in a healthy population, studies
of risk factors associated with the effects of marijuana use on the liver in healthy
populations are relatively scarce in the literature. For example, when Kim et al. (2017)
showed that marijuana use is associated with NAFLD and Tarantino, Citro, and Finelli
(2014) found that marijuana use potentially creates health risk in patients with
concomitant chronic liver diseases, neither study assessed how the difference in the
amount of marijuana use, the length of time it was used, and how the age of initiation
may have differently affected the study results. In addition, these studies did not assess
the risk factors associated with individual liver function markers, as each of them may be
indicative of other liver health issues.
To close the gap in the literature, the intent of this study was to identify potential
predictors of the health effects of marijuana use on hepatic function while examining the
association between the number of joints or pipes of marijuana smoked daily, the age of
initiation, the length of time the drug was used, and the individual liver function markers
using a large nationally representative sample.
Purpose of the Study
The purpose of this study was to identify potential predictors of the liver health
effects associated with marijuana use on hepatic function, while also examining the
effects of the number of joints or pipes use daily, the age of initiation, and the length of
time marijuana was used. In a cross-sectional analysis, this study used the number of
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joints or pipes smoked daily, the age of initiation, and the duration of use as the
independent variables, and the biochemistry profile of the liver, including the serum level
of ALT, AST, ALB, ALP, TB, TP, and GGT were used as the outcome variables. I
categorized the population sample by the age of the study participants, the age of
initiation, and the length of time the drug was regularly used. The study approach reduced
bias or the possible confounding effects of liver risk factors by controlling for aging
factors, gender, alcohol use and body mass index (BMI).
Research Question
The research question addressed in this study was as follows: Is there any
significant association between the number of joints or pipes of marijuana smoked in a
day, the age of initiation, the duration of use and each of the serum level of liver function
markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and GGT while
controlling for the age of participants, their gender, the average alcohol use and BMI?
H01: There is no significant association between the number of joints of marijuana
smoked in a day, the age of initiation, the duration of use and each of the serum level of
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and
GGT while controlling for the age of participants, their gender, the average alcohol use
and BMI.
H11: There is significant association between the number of joints of marijuana
smoked in a day, the age of initiation, the duration of use and each of the serum level of
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and
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GGT while controlling for the age of participants, their gender, the average alcohol use
and BMI.
Theoretical Framework
This study was grounded in the ecosocial theory introduced by Krieger in 1994
(Krieger, 2011). The key premise of this theory is that the pattern of health and disease
can be explained by a complex web of interconnected risk and protective factors rather
than by direct causative agents (Krieger, 2011). The theory explains how exposure to
certain commodities, such as tobacco, alcohol, and illicit drugs are possible pathways that
affect the physiology and gene expression in humans, which, in turn, affects their health
outcomes (Krieger, 2011).
The major construct of ecosocial theory, embodiment, entails the claim that
disease and health pattern are the results of what humans biologically embody during the
course of their life and that disease can be explained not only by innate factors, but also
by the effects of exogenous factors on the human body (Krieger, 2011). Alongside the
core construct, the theory calls for attention to the joint interplay of exposure,
susceptibility, and resistance at multiple levels across the course of a person’s life
(Krieger, 2011). Acknowledging the pathway of the joint interplay of exposure,
susceptibility, and resistance helps to identify exposures, potential confounders, and
effect modifiers concerning the social group, time, and place (Krieger, 2011). It is also a
critical pathway for evaluating the likely impact of risk factors on disease burden
(Krieger, 2011). The theory allows for better conceptualization to examine risk factors
associated with diseases at the individual and population levels (see Figure 1).
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Adapting ecosocial theory to this study reveals that understanding the health
effects of marijuana use on the liver requires the examination of the social and biological
risk factors that mediate the relationship between marijuana use and hepatic function (see
Figure 1). The embodiment construct facilitates a better understanding of the major
factors that are associated with marijuana use. Kalant (2004) reported that the early onset
of marijuana use, especially weekly or daily use, are strong predictors of future adverse
health effects, and Borini et al. (2004) found that the health effects of cannabis depend on
the dose received. The interconnection of these risk factors and their roles in the
physiology and gene expression in the human body are evidence of adverse health
outcomes such as liver diseases. Hall (2009) observed that it is challenging to assess risk
factors associated with adverse health outcomes of cannabis use only because users are
also likely to use alcohol, tobacco, and other illicit drugs. This observation points to the
potential presence of confounders and/or effect modifiers concerning risk-factor
assessment and analysis in marijuana users, which Krieger (2011) proposed to elucidate
or evaluate using the pathway of the joint interplay of exposure, susceptibility, and
resistance (see Figure 1).
This theoretical framework provides the basis to understand the exposures to
marijuana use and to evaluate associated risk factors and their impact on the hepatic
function.
Considering the key premise of ecosocial theory that exposure to certain risk
factors affects the physiology and gene expression in humans, which are the source of
many diseases (Krieger, 2011), with the exposure pathway that called attention to the
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joint interplay of exposure, susceptibility, and resistance, the results of this study are
expected to provide insight into how the age of initiation, the daily dose of marijuana use,
and the frequency at which marijuana is used affect liver function of users.

Figure 1. Ecosocial theory and embodying inequality: core constructs. (Krieger, 1994;
Krieger, 2008). Reprinted from Krieger, N. (1994). Ecosocial Theory of Disease
Distribution. In N. Krieger (Ed), Epidemiology and people’s Health: Theory and Context
(pp. 202-235). New York, NY: Oxford Press.
Nature of the Study
The study had a primarily quantitative cross-sectional design with a focus on
secondary data collected from the National Health and Nutrition Examination Survey
(NHANES, National Center for Health Statistics [NCHS], 2015b). Data analysis will take
into consideration several parameters that assess the risk of developing liver diseases
when the organ is exposed to marijuana use. The study will consider only sample
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participants aged 20 to 59 years old. An approach of data analysis will use a complex
sample general linear model (CSGLM) in SPSS where the outcome variables need to be
continuous and the predictor variables can be categorical or continuous. The CSGLM
takes into consideration the multistage sampling method use during the NHANES data
collection. A deep analysis of the statistical tools and the effects of confounding variables
will be considered and assessed later during the study.
Definition of Variables
In this section, I define the key variables in the context of this project.
Independent Variables
Number of joints or pipes smoked daily: In the context of this project, this
variable is related to the number of joints or pipes of marijuana or hashish, an individual,
male or female aged 20 to 59 years smoked in a day.
Age of initiation: This is the age at which an individual, male or female, aged 20
to 59 years, began regularly using marijuana or hashish.
Duration of marijuana use: This was the period in a lifetime when marijuana was
used.
Dependent Variables
Alanine aminotransferase (ALT): ALT is a circulating transaminase in human
serum and a specific marker for liver dysfunction (Huang et al., 2017). According to the
NHANES data documentation and description, an elevated level of ALT can be
indicative of hepatic disease, myocardial infarction, and/or muscular dystrophy and organ
damage. In the context of this study, ALT will be assessed to diagnose liver disease.
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Aspartate aminotransferase (AST): As a liver enzyme, AST increased during liver
dysfunction. Apart from being elevated in liver diseases, the activity of the enzyme is
also influenced by certain disease states, such as myocardial infarction, muscular
dystrophy, pulmonary emboli and acute pancreatitis (Marshall, Lapsley, Day, & Ayling,
2014). In the context of this study, AST will be used uniquely for its ability to diagnose
liver disease.
Alkaline phosphatase (ALP): Alkaline phosphatase is another enzyme used as part
of liver function analysis to evaluate possible dysfunction of the liver (Bishop et al.,
2018; Lowe & John, 2018). Because it is a nonspecific enzyme, 80% of ALP found in the
serum originates from the liver, bones, and in small amounts from the intestine. The
enzyme serves as a marker of extrahepatic cholestasis such as stones in the bile duct or
intrahepatic cholestasis such as drug-induced cholestasis or biliary cirrhosis (Bishop et
al., 2018; Lowe & John, 2018; Sharma, Pal, & Prasad, 2014). The enzyme will be used in
the context of this study to evaluate liver dysfunction.
Total protein (TP): Synthesized in the liver, the evaluation of serum total protein
is useful to assess the synthetic ability of the liver. Although the protein level is not a
sensitive marker for liver damage, it is useful to quantify the severity of liver dysfunction
(Bishop et al., 2018). In the context of this study, TP will be used to evaluate liver
dysfunction.
Albumin (ALB): Synthesized by the liver, Albumin is the major form of protein in
human serum, which is involved in maintaining proper osmotic pressure and the transport
of various substances through the body (Bishop et al., 2018; Morman & Varacallo, 2018).
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A low concentration of albumin is most commonly associated with possible liver disease
(Morman & Varacallo, 2018). In the context of this study, the level of serum albumin will
be employed as a liver disease marker.
Total bilirubin (TB): Bilirubin is a breakdown of old and damaged red cells
collected in the liver. Sometimes the body can have an excessive amount of bilirubin,
which is referred to as hyperbilirubinemia and recognized as jaundice (yellow
discoloration of the skin, eyes and mucous membranes) when the excess is accumulated
in the tissue (Bishop et al., 2018). According to the NHANES data documentation and
description, elevated bilirubin is associated with hemolytic jaundice, internal hemorrhage,
acute hemolytic anemia, while low bilirubin is associated with chronic nephritis and
aplastic anemia. In the context of this study, variations in bilirubin levels will be
exclusively measured to assess the presence of liver-related diseases.
Gamma-glutamyl transaminase (GGT): Elevated activity of GGT is found in liver
dysfunction, hepatobiliary disorders and chronic alcohol consumption (Bishop, 2018;
Koenig & Seneff, 2015). A drug such as warfarin, phenobarbital, and phenytoin are noted
to increase the enzyme level. According to the NHANES data documentation and
description, GGT is the most sensitive marker of liver disease.
Controlled Variables
Alcohol use: In the context of this study, alcohol consumption is categorized into
light drinkers (less than 2 drinks per day), moderate drinkers (2 to 4 drinks per day), and
heavy drinkers (4 or more drinks per day). One drink is defined as a 12-oz beer, a 5-oz
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glass of wine, or 1.5 oz of liquor (National Institute on Alcohol Abuse and Alcoholism,
n.d.)
Body mass index (BMI): In the context of this study, BMI refers to the weight in
kilograms of any participant divided by his or her height in meters squared, rounded to
one decimal place.
Age: In the context of this study, age refers to the age of the participants at the
date of screening.
Gender: In this study, the gender of the participants can be male or female.
Definition of Terms
Marijuana: Also known as weed, herb, pot, grass, bud, ganja, and “Mary Jane,”
marijuana refers to the dried leaves, flowers, stems, and seeds from the hemp plant,
Cannabis sativa. Marijuana used in a hand-rolled cigarette is referred to as a joint, and it
is referred to as a pipe when used in pipes or in water pipes.
Delta-9-tetrahydrocannabinol (THC) is the main psychoactive chemical,
responsible for the intoxicating effect found in marijuana. It is mainly found in the resin
produced by the leaves and buds of the cannabis plant.
Hepatitis is an inflammation of the liver. There are many types of hepatitis
depending on etiological factors. Viral hepatitis is caused by a viral infection, and
depending on the type of virus, viral hepatitis can be subdivided into hepatitis A through
E. Alcoholic hepatitis, caused by increased alcohol consumption is also common. Other
medical conditions such as autoimmune diseases can also cause inflammation of the liver
Snyder, 2016).
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Assumptions
Although the different markers employed in this study are known in the diagnosis
and treatment of other diseases, they were exclusively used in this study for their function
in liver-related diseases.
The age of initiation or the age of onset usually refers to the age at which an
individual had the first contact with marijuana or hashish. But in the context of this study,
the age of initiation or the age of onset was assumed to be the age at which an individual
had contact with marijuana or hashish and continued using it for at least one year.
Scope and Delimitations
This study was limited to participants aged 20-59 years old, ages at which
marijuana use may not have a considerable effect on the liver. Younger or older members
of the population may display a different pattern of the effect of marijuana on the liver.
This study was also unable to account for the difference in the size of joints or pipes of
marijuana and the variation in the daily amount used. Furthermore, this study does not
consider any gender difference when assessing the data. Although the gender-related
health effect of marijuana on the liver could be mentioned during analysis, it is not the
fundamental objective of this study.
Participants who tested positive for hepatitis B and C were excluded from the
study because such individuals may develop an increased level of liver enzymes that
could interfere with the study results. It has been proven that these patients develop an
increased level of ALT and AST (Bishop et al., 2018). Other liver diseases, such as
NAFLD, liver cirrhosis and liver cancer also commonly increase the level of liver
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enzymes (Bishop et al., 2018). Unfortunately, data on these diseases which could have
improved the relationship between the different variables were not available to introduce
them in the current study for analysis.
In brief, this study could not establish a cause-effect relationship, but it was
designed to be capable of identifying associations between possible predictors and
outcome variables (Asomoah, 2014).
Limitations
In any research study, it is important to acknowledge the limitations. These
limitations should focus on the problems related to the research question(s) being studied
(Connelly, 2013). The NHANES data have an important number of missing marijuana
use data due to the sensitivity of the drug use questionnaires. For this study, I ignored any
case with one or more missing data points, which evidently reduced the sample size. To
avoid possible selection bias caused by such procedure, I considered and combined data
collected over several years (2009 to 2016). To make the data representative of the
general population and as recommended by the NHANES, I adjusted the dataset for the
weight to indicate the combination of four years of data collection cycles.
It is important to note that the NHANES data were self-reported answers to a
series of questions. Although subjected to many processes of verification to ensure
accuracy, self-reported data are always prone to bias (Connelly, 2013).
Significance of the Study
An increase in the number of people consuming illicit drugs was reported in 2013
by the NIDA (2015). The increasing decriminalization of marijuana was identified as a
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major contributing factor to the rise of the drug consumption (Maier et al., 2017). More
than 11 million Americans used marijuana in 2015 alone (NIDA, 2015). While alcohol
drinking, tobacco smoking, and cocaine use have decreased over the years (NIDA, 2015),
marijuana use is on the rise, which has resulted in more cannabis-related emergency
department visits (Ayangbayi et al., 2016). Not only was research on the health effects of
marijuana on the liver scarce in the literature, but the findings in the studies that were
available were also conflicting. Although some findings suggested a therapeutic effect of
the drug on the liver (Adejumo et al., 2017; Kim et al., 2017), other findings warned of its
adverse effects on human health (Wolkow et al., 2014). Researchers also lack approaches
to assess possible predictors such as the age of initiation, the quantity of marijuana use,
and the duration for which it was used in the analysis of the health effects of marijuana
on hepatic function.
By analyzing the impact of the age of initiation, the quantity of marijuana use, and
the duration for which marijuana was used on the individual liver enzymes, this study
was intended to provide insight on the predictors of the health effects of marijuana on the
liver. Liver enzymes were assessed individually because each of them indicates a
different health status of the liver.
Summary
In Chapter 1, I presented the scope of the study, including the nature and the
different assumptions of the study. In Chapter 2, the literature review, the state of
marijuana use in the United States and its related issues are first discussed. Thereafter,
findings from recent studies are explored, which are related to how the age of initiation of
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marijuana, the amount of marijuana used, and the length of time during which marijuana
was used appear to have an effect in the health effect of marijuana on the biological
markers, including the serum level of ALT, AST, ALB, ALP, TB, TP and GGT.
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Chapter 2: Literature Review
Introduction
The purpose of this literature review is to find articles related to the key variables
of the study topic and use them to demonstrate that there is a significant gap in the
literature regarding the predictors of the health effects of marijuana on hepatic function.
In addition, this literature review serves as a broad overview of the new developments
regarding the association between marijuana use and liver disease. This literature review
also evaluates the role played by the key variables, including the age of participants, age
of initiation, duration of marijuana use, and ALT, AST, ALP, TP, TB, ALB, and GGT in
similar studies.
Organization of the Review
This literature review first presents an overview of the state of marijuana use and
related issues in the United States. For a better understanding of the health effects of
marijuana use on the liver, I also evaluate current studies on the possible association of
marijuana use and liver diseases including NAFLD, hepatitis-C infection, liver fibrosis,
and liver cirrhosis. I then provide an overview of liver diseases and risk factors.
Additionally, after a brief review of the key variables, the literature review includes an
evaluation of the role played by the age of participants, the age of initiation, the duration
of marijuana use, and the dose of marijuana use in liver diseases. Finally, I examine the
effect of marijuana use on the different outcome variables including ALT, AST, ALP,
TP, TB, ALB, and GGT.
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Literature Search Strategy
Articles on the health effects of marijuana on hepatic function were found by
searching online databases such as MEDLINE, CINAHL, and Google Scholar. I selected
only peer-reviewed articles using keywords such as cannabis, marijuana, THC, pot or
weed, liver, liver disease, liver function parameters, ALT, AST, ALP, TP, ALB, TB, and
GGT. Multiple combinations of the keywords were used to identify potential articles on
the association between the independent and outcome variables. Recent peer-reviewed
articles on possible covariables were also identified using a combination of keywords,
including alcohol, tobacco, liver, liver function parameters, and marijuana. I also
identified several articles from the U.S. National Library of Medicine (NLM) and the
National Institute of Health (NIH).
A combined search of MEDLINE and CINHL limited to 2013-2019 using the
keywords marijuana, cannabis, pot, weed, and THC, cross-searched with keywords liver
disease, or liver failure, or liver cirrhosis yielded 78 peer-reviewed articles. The full-text
articles identified narrowed the count down to 56 articles (42 articles in MEDLINE and
14 in CINAHL). Among the 56 articles, 45 were considered relevant to the study either
by elucidating the variables in the study or serving as a ground of possible association
between predictors and response variables. The articles also served to demonstrate the
existing gap or to make a case for the significance of the study. Through cross-searches
using the same keywords in Google Scholar for the same period, I obtained 49 results
consisting of articles and books. A combination of approximately 20 articles and books
were considered relevant and introduced into the literature review. A search of the term
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marijuana and the individual outcome variables (ALT, AST, ALB, ALP, TP, TB, GGT)
yielded less than 15 results for each variable in MEDLINE and CINHL, which was also
the case with the Google Scholar search. Approximately five articles per outcome
variable were found to be relevant to the study. The same keywords were cross-searched
in the U.S. NLM and NIH (PubMed) websites, and although some of the articles found
had already been identified in the MEDLINE, CINHL and Google Scholar searches, I
identified approximately 30 new relevant articles. A few articles related to the
confounding variables through multiple combinations of the keywords alcohol, tobacco,
marijuana and liver disease, liver failure, or liver cirrhosis were selected.
Theoretical Foundation
This study was grounded in the ecosocial theory introduced in 1994 by Krieger.
The theory explains the cause of diseases, disease patterns, and disease distributions as an
interconnected web of social and economic exposure through the course of the lives of
the individual or population (Krieger, 2011). Unlike other disease etiology theories that
connected disease occurrence to the interrelation between host-agent and environment
(Egger, Swinburn, & Rossner, 2003), the ecosocial theory depicts a new
multidimensional and more dynamic perspective of the cause of diseases, disease
patterns, and disease distributions. The theory was based on four major propositions.
The Core Propositions of the Theory
The core propositions of the ecosocial theory are based on a multidimensional and
dynamic perspective in the inquiry and analysis of the changing pattern of population
health (Krieger, 2001). The first core proposition, embodiment, posits the idea that
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human beings embody their life experiences, which, in turn, affect the disease patterns.
The idea of embodiment is a recognition of the continued interaction between the human
body and its environment. This interaction along the course of life is manifested at
different levels and affects disease patterns. This interaction has a primary consequence
of changing both gene regulation and expression (Krieger, 2001). The proposition of
embodiment is that the determinants of disease patterns and distributions are exogenous
to people's bodies and cannot solely be limited to the biological characteristics but also to
the societal context (Krieger, 2001). The second core proposition of the theory suggests
that there are multiple pathways of embodiment. The pathway of embodiment brings
attention to the idea that specific exposures, including, for instance, exposure to toxic
substances, social and economic precarity, cause poor health. The third core proposition,
the joint interplay of exposure, susceptibility, and resistance, calls attention to the time it
takes for the body to respond to the embodied materials, including change in gene
expression. The fourth core proposition, accountability, calls on how health disparities
should be monitored and analyzed. It also calls attention to the political and economic
driving force of health-related issues, which represent grounds for the changing patterns
in health.
Ecosocial Theory and Marijuana Use
The ecosocial theory has been used as grounds for inquiries in several social
sciences, medicine, and environmental studies. Developed to address the question of
“who and what drives social inequalities in health,” the theory has been central in
facilitating inquiries about the changes in the population’s health patterns (Krieger,
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2011). The theory has been used across different population groups including different
age, gender, and ethnicity groups. Inquiries into the distribution in infectious, acute, and
chronic disease have also seen the use of the ecosocial model. Epidemiological factors, as
well as environmental factors, have been evaluated across multiple health issues using the
ecosocial theory as a model of inquiry. Gomaa et al. (2016) assessed the cause of oral
health inequality using the core proposition of the ecosocial theory, making the case that
inquiries based only on biomedical and behavioral approaches to understand oral health
inequality were ineffective. The authors analyzed a pathway through which social factors
affected oral health outcomes, became embodied, and altered biological factors, including
the expression of genes (Gomaa et al., 2016). The theory has also been a driving force in
the development of new perceptions during illicit drug use inquiries (Duff, 2007; Ettorre,
2004). For example, like Krieger (2005) who emphasized that the body tells stories, Duff
(2007) studies drug use by the female gender and reported that the human body is a social
identity and means of self-expression. Ettorre (2004) found that different factors were
associated with drug use, including the cost of the drug, the availability of the drug, the
level at which the body desires the drug, social exclusion, and the culture of the drug use
which later, he stated, becomes embodied experiences. The first major proposition of the
ecosocial theory, embodiment has been applied in different drug use, substance use,
intoxication, and addiction studies, while also emphasizing the social and environmental
context in which users live (Angus, 2013; Duff, 2007; Ettorre, 2004).
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The Rationale of Choosing the Ecosocial Theory
Human bodies often tell stories that may not be consistent with their assertion,
and these stories should be studied in the context of the individual’s course of life
(Krieger, 2005). The ecosocial theory explains disease patterns by emphasizing on social
and biological interactions. In addition, several authors linked the predictors of drug use
to social factors and the environment in which the users live (Angus, 2013; Duff, 2007;
Ettorre, 2004). Consequently, understanding the predictors of marijuana use on the
hepatic function required the examination of the user’s adverse factors exposure. In her
theory, Krieger (1994) also stipulated that, once embodied, the adverse exposures altered
gene expression as the source of diseases. In this study, the predictors once embodied
may affect gene expression and alter hepatic function. In brief, exposure to illicit drugs
such as marijuana is a potential pathway that affects the physiology and gene expression
in certain users, which in turn, affects the condition of their health. Like many recent
studies (Adejumo et al., 2017; D. Kim et al., 2017), the current study broke with studying
disease burden while relying only on the biological factors. The examination of social
and biological interactions during disease pattern inquiries helped to identify risk factors
or potential predictors of the health effects of marijuana use on hepatic function. The
embodiment and the pathways of embodiment constructs helped to understand how once
embodied these risk factors altered the biology of gene expression, which can be the
source of adverse health outcomes. The third construct, the pathway of the interplay of
exposure, susceptibility, and resistance helped the study to frame the presence of
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potential confounders and/or effect modifiers concerning risk factors assessment and
analysis in marijuana users.
The ecosocial theory not only provides a new perception in the study of potential
effects of marijuana use on the liver but also guides to understand that during the human
course of life, risk factors are embodied and altered the biology of gene expression,
which are a source of diseases.
Marijuana Use: State of the Problem
Marijuana is the oldest and most widely used illicit drug in the world (NIDA,
2015). Historically, it was available in the U.S. around 1900 (Chasteen, 2016), and as of
2015, more than 11 million Americans used the drug (NIDA, 2015). With the increasing
decriminalization of marijuana, it is imperative to reevaluate the health risks and health
benefits associated with the drug.
In recent years, there has been a change in perceived risk associated with the use
of marijuana, and people who believe that marijuana use is associated with health risk is
decreasing (Okaneku et al., 2015). Okeneku, et al. (2015) analyzed the data from 2002 to
2012 from the National Survey on Drug Use and Health (NSDUH) and found a
significant decrease in perceived risk in occasional and regular marijuana users. When
the model was stratified by age, gender, and their past month of use, the study revealed
that decreases in the perceived risk of marijuana use were associated with younger age,
male gender, and past their month of use. The study associated such decreases in risk
perception to the change in marijuana laws. There was a marginally significant increase
in young adults’ acceptance of marijuana use because of the implementation of medical
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marijuana laws and a perception that marijuana use has no or low risk (Wen,
Hockenberry, & Druss, 2018). In Washington and Colorado, where recreational
marijuana has been legalized, Washington has seen an increase in adolescent marijuana
use when Colorado pre- and post-legalization saw no change (Cerdá et al., 2017).
Marijuana use is on the rise compared to the other illicit drug use in the U.S. In
2011, the Drug Abuse Warning Network (DAWN) reported 455,668 emergency
department visits related to marijuana use, representing a 52% increase between 2004 and
2011 and 36% of all non-alcohol illicit drug emergency department visits (SAMHSA,
2014). In 2015, the SAMHSA reported 157,733 marijuana/hashish-related admissions in
hospitals or residential service treatments. Overall, the prevalence of marijuana
consumption more than doubled from 2001-2002 to 2012-2013 (SAMHSA, 2014). This
significant increase has been observed across all population subgroups (sex, age,
race/ethnicity, education, marital status, income, urban/rural, and region) (SAMHSA,
2014). During that same period, there was a significant increase in marijuana use
disorders (Hasin et al., 2015). Interestingly, between 1990-1991 and 2001-2002, the
prevalence of marijuana was stable with an increase in marijuana use related disorders.
This inverse result seen during the two-study periods suggested the presence of a new
factor, which several scholars have associated with the increase in potency of marijuana.
In fact, ElSohly et al. (2016) found that the THC potency in marijuana on the illicit
market has consistently increased from approximately 4% in 1995 to 12% in 2014 .When
assessing the issues related to such an increase in potency in illicit marijuana, Wolkow et
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al. (2014) concluded that the health consequences of marijuana may be worse now than
in the past.
Although multiple studies have reported adverse effects from the use of
marijuana, many other studies have found positive health effects from the use of the drug.
Wolkow et al. (2014) published a report that addressed the adverse effects of marijuana
use, including its effects on the brain development, the risk of cognitive impairment,
altered mental health, diminished life satisfaction, poor educational outcomes, and the
development of symptoms of chronic bronchitis. The report also acknowledges the health
benefit of marijuana use, including its ability to relieve the symptoms of glaucoma,
nausea, chronic pain, inflammation, multiple sclerosis, and epilepsy. However, Volkow
and his colleagues suggested making better use of the medical benefits of marijuana to
avoid exposing people who are sick to the intrinsic negative effects of the drug.
Although some studies have reported beneficial health effects of marijuana, and
other reported adverse health effects, the issues associated with the health effects of
marijuana on the human body remain the subject of heated debates among scientist and
policymakers.
An Overview of Liver Diseases and Risk Factors
The major causes of liver disease are related to a variety of factors, include an
increase and continued consumption of alcohol, autoimmune disorders, viral infections,
drug-related causes and non-alcoholic accumulation of fat in the liver cells. (Fumeaux et
al., 2018; Wang, Fan, Zhang, Gao, & Wang, 2014). Common liver diseases are hepatitis
B virus (HBV), HCV, alcoholic and nonalcoholic liver disease, cirrhosis and
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hepatocellular carcinoma (Wang et al., 2014). The liver is the largest and the most
important organ in the human body. It performs more than 500 vital functions that range
from cleaning toxins from the blood and providing the body with nutrients to storing
energy by participating in the metabolism of carbohydrate, lipid, and protein (Snyder,
2016; Woldin, 2014).
It is important to note that liver disease can be acute or chronic. Acute liver
disease can develop into chronic. For example, viral hepatitis such as hepatitis A through
E are considered acute viral diseases. However, Hepatitis B and C can progress into
chronic hepatitis due to the continued and longtime inflammation of the liver (Snyder,
2016). In addition, heavy alcohol consumption can also progress from acute liver disease
to a chronic liver disease which is manifested by cirrhosis of the liver (Snyder, 2016;
Woldin, 2014). In brief, three different scenarios can occur when someone is diagnosed
with acute liver disease. Either the liver recovers from the acute inflammation process
within a few weeks or few months or gets worse very quickly (fulminant hepatitis). In
certain other conditions, acute liver disease can elevate to a chronic disease such as
chronic hepatitis-C or cirrhosis (Snyder, 2016) which can lead to liver cancer or liver
failure.
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Figure 2. Liver diseases.
Current Studies on Marijuana Use and Liver Disease
Several studies in recent years are finding more about the positive health effects
of marijuana (Adejumo et al., 2017; Kim et al., 2017). However, the question remains
whether the health benefits of marijuana seen in recent years outweigh the negative
health effects that have pushed U.S. health institutions and institutions around the world
to consider marijuana as a Schedule I drug (SAMHSA, 2014). Findings of the health
effects of marijuana on the liver vary from negative, positive, or no significant health
effects, depending on preexisting liver conditions of the population studied (Kim et al.,
2017; Pateria, de Boer, & MacQuillan, 2013). Most of the researchers evaluated the
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effects of the marijuana use on individuals with preexisting liver conditions such as
NAFLD, hepatitis C, and liver cirrhosis and have found different results.
The Effect of Marijuana on Nonalcoholic Fatty Liver Disease (NAFLD)
NAFLD is an inflammation of the liver that is not caused by alcohol but by the
accumulation of fat in the liver (Bull, 2013). NAFLD can progress into nonalcoholic
steatohepatitis (NASH) which is more prone to the development of cirrhosis (Pattnaik et
al., 2018). Possible risk factors are diabetes mellitus, metabolic syndrome, high blood
pressure and hyperlipidemia (Al-Dayyat, et al., 2018; Pattnaik et al., 2018). With the
increasing level of obesity, NAFLD has emerged as the most common chronic liver
disease in the developed world (Ajmera & Loomba, 2017). With the exception of a few
clinical studies published before 2010 (Purohit et al., 2010) that found that smoking of
marijuana may be detrimental to the liver and increase the risk of developing NAFLD,
most recent epidemiological studies are finding that the consumption of marijuana has a
therapeutic effect on the health of the liver (Adejumo et al., 2017; Kim et al., 2017).
When analyzed the function of the endocannabinoid system that comprises the CB1 and
CB2 receptors, a clinical study found that marijuana use may be detrimental and
constitute a risk factor for NAFLD (Purohit et al., 2010). CB1 and CB2 are
phytocannabinoids receptors of THC, the principal cannabinoid compound found in
marijuana (Mallat & Lotersztajn, 2010). CB1 and CB2 receptors play a key role in
hepatic steatosis, hepatic inflammation, and liver fibrogenesis (Alswat, 2013). No recent
population-based studies, at least up to and included in this review, have found
detrimental effects of marijuana on NAFLD. Instead, several recent population-based
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studies have found therapeutic health effects associated with marijuana on the liver of
NAFLD patients. In a cross-sectional study, when exploring the 2014 National Inpatient
Sample (NIS) data to analyze the possible association between cannabis use and NAFLD,
Adejumo et al. (2018) indicated that cannabis use is associated with a significantly lower
prevalence of NAFLD with an adjusted odds ratio of 0.82. The findings suggest that
cannabis has a suppression or reversal effect on the development of NAFLD. These
findings are in line with the study results conducted by Donghee et al. (2017). Both
studies used different data, though they found the same therapeutic effect of cannabis as a
result of their investigations. When using the NHANES data, Donghee et al. (2017) found
that marijuana users were less likely to be suspected of having NAFLD with an odds ratio
(OR) of 0.90 (95% CI: [0.82-0.99]), and 0.68 (95% CI: [ 0.58-0.80]), respectively, for
past and current users. The analysis of age, gender, and an ethnicity-adjusted model of
ultrasonography-diagnosed data also revealed an inverse association between NAFLD
and marijuana with an OR of 0.75 (95% CI: [0.57-0.98]) for current users. A similar
trend was observed when current light and heavy users were compared to non-users. The
results of the study also strongly suggested that the inverse association observed is
independent of BMI value, educational level, economic status, smoking status, alcohol
consumption, diabetes, hypertension and current use of cocaine. This independent
association of marijuana with NAFLD was also the result of a population-based study
conducted by Adeyinka et al. (2017), which reported a lower prevalence of NAFLD in
cannabis users utilizing the Nationwide Inpatient Sample (NIS) of the Healthcare Cost
and Utilization Project (HCUP). In addition to comparing cannabis users to nonusers, this

32
latter study has differentiated between dependent cannabis users and nondependent
cannabis users and found a dose-response effect of cannabis on NAFLD. Dependent
cannabis users are less likely to have NAFLD when compared to nondependent cannabis
users. Because alcohol is known as a predictor of a higher prevalence of NAFLD
(Adeyinka et al., 2017), the analysis of cannabis use on NAFLD in alcohol-dependent
and nondependent patients has indicated that only nondependent alcohol users gain the
benefit of the therapeutic effect of cannabis use.
The Effect of Marijuana use on Hepatitis C
Like in NAFLD, patients with hepatitis-C infection can also advance to the
fibrosis stage or liver steatosis (Liu et al., 2014). With knowledge of the health effects of
substance abuse on the liver, several researchers also examined the health effects of
marijuana on the liver of hepatitis-C patients, and interestingly found conflicting results.
A recent Canadian study found that marijuana use is not a predictor of liver
steatosis, inflammation or the advancement to the fibrosis stage in hepatitis-C patients
using liver biopsy data of 550 patients with whom 159 individuals were self-reported
marijuana users. Instead, the study found that the age of the patients, HIV seropositive
status, and history of intravenous drug use were predictors to the advanced stage of
fibrosis in hepatitis-C patients (Liu et al., 2014). Unlike the above study, while examining
the NIS of U.S. adult patients infected with chronic hepatitis C virus, Adejumo et al.
(2018) demonstrated that cannabis use reduced the incidence of cirrhosis caused by HCV
infection. The study also demonstrated that cannabis use reduced the prevalence of
cirrhosis due to HCV infection including a reduction in the prevalence of ascites, variceal
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bleeding, hepatorenal syndrome, hepatic encephalopathy, portal hypertension, and
jaundice. Overall, reduction in inpatient mortality, length of hospital stay, and total health
care costs have all been associated with marijuana use in HCV infection patients
(Adejumo et al., 2018).
Marijuana and the Key Independent Variables
This portion of the existing literature review examines the influence of the age of
marijuana user, the age of initiation of marijuana use, the quantity and the duration of
marijuana use on the health condition of the liver.
Marijuana, the Age Factor, and Liver Disease
The age of marijuana users and the age of onset of marijuana use are at the core of
the discussions regarding the effects of marijuana on human health (Johnson et al., 2015).
Age has been found to be a risk factor for many chronic diseases including liver diseases.
For example, Cheng et al., (2013) found increased prevalence of metabolic syndrome and
fatty liver disease among the elderly population. In the United States, there was a modest
decrease in the prevalence of marijuana use from 1999 to 2009, yet there was a steady
increase since 2009. During that same period, adolescent use of marijuana has also
decreased (Johnson et al., 2015). However, the age-specific onset of marijuana use has
varied throughout recent history. The percentage of adolescents who tried marijuana
before the age of 13 years increased from 1991 to 1999 but has seen a steady decrease
from 1999 to 2015 (YRBSS, 2017). When assessing how marijuana affects the
prevalence of NAFLD in two different subgroups (< 40 vs. > 40), the study found that the
younger population (less than 40 years old) who heavily used marijuana displayed a 35%

34
reduction in risk of prevalence of NAFLD compared to a 26% reduction in the older
population (greater than 40 years old) (Kim et al., 2017). Contrary to the above findings,
Kotan et al. (2017) presented the results of the effect of cannabis use on 34 cannabis
users who used cannabis for the first time at age 21.8 years (SD 5.0); after an average of
more than 30.5 months of use, the patients still displaying close to normal liver function
parameters. In other hands, Quraishi et al. (2013) found that at the age of initiation of
15.31 years (SD 4.7), and after using cannabis for more than 9.53 years (SD 8.06), 51%
of cannabis dependent patients showed abnormal liver-related parameters. These findings
suggested that the age of marijuana users, the age of initiation and the duration of the
substance use introduced some degree of variation in the effects of marijuana use on the
health condition of the liver.
The Duration of Marijuana Use and Liver Disease
Addressing the marijuana-related health issues requires a better understanding of
how much and how long people use marijuana during their lifetime and the degree to
which it was used (NIDA, 2018). Terry-McElrath et al. (2017) associated increased risks
of negative health outcomes in 50 years old marijuana users with moderate or heavy
long-term use of marijuana. As previously mentioned, Quraishi et al. (2013) and Kotan et
al. (2017) have shown that the duration of cannabis use is a predictor of the impact on
liver health associated with the use of marijuana. Kotan et al. (2017) have found no
negative health outcome at a mean duration of cannabis use of 30.5 months whereas
Quraishi et al. (2013) found detrimental health effects at a longer duration of cannabis
use of 9.53 years (SD 8.06). In addition, a Sudanese case-control study showed a strong
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correlation between the duration of marijuana use and liver enzyme activity. The study
found a significant difference in the activity of the enzymes of the control group
compared to the subject group using 120 samples (60 samples of abusers and 60 samples
of control cases) (Mohamed et al., 2015).
The Quantity of Marijuana Use and Liver Disease
The quantity of marijuana use is another factor at the core of the health effects of
marijuana on users (Terry-McElrath et al., 2017). Out of 14,080 NHANES participants,
Donghee et al. (2017) found that 56.1%, 36.9%, and 7% respectively reported never used,
used in the past, and current users of marijuana. Of the 7 percent who reported currently
using marijuana, light users represented 4.9 %, while heavy users represented 2.1%.
When the study assessed the association between dose-dependent marijuana consumption
and suspected NAFLD, the prevalence rates of suspected NAFLD were 30.5%, 38.0 %,
and 40.7 %, respectively, in current light users, past users and those individuals who
never used. The results were consistent when ultrasonography diagnosed NAFLD data,
with 23.2%, 29.4%, and 35.0%, respectively, in current light users, past users and those
individuals who never used. In brief, it has become apparent that current or past
marijuana use has been significantly associated with a lower risk of the suspected
NAFLD. In addition, when the study assessed only current users, light users were
reportedly inversely associated with NAFLD, while there was no significant association
with heavy users due to the small number of heavy users among the participants. The
results of this study were consistent with the results of a study conducted by Adejumo et
al. (2017), which analyzed the association with NAFLD in three categories of users (non-
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cannabis users, nondependent cannabis users, and dependent cannabis users) using the
2014 HCUP data of 5,950,391 participants. After adjusting for possible covariates, the
study found a 43 % lower prevalence (AOR: 0.57[0.42–0.77]; p < 0.0001) of NAFLD in
cannabis-dependent users compared to nondependent users, suggesting that heavy
cannabis use has a positive effect factor on the prevalence of NAFLD. In addition to
NAFLD patients, a study conducted in Canada found that in HCV positive patients,
cannabis users have the lowest frequencies of liver cirrhosis when compared to nonusers.
In a dependent and nondependent category comparison, the prevalence of liver cirrhosis
decreased by 15 % and 48% respectively among nondependent and dependent users
(Adejumo et al., 2018). By contrast, Liu et al. (2014) found no significant difference in
biopsy fibrosis, liver inflammation, and steatosis in 21 HCV positive patients classified as
“high daily marijuana users” (> 1 g /day for marijuana use) compared to non-current
marijuana users. Terry-McElrath et al. (2017) also demonstrated that the intensity of
marijuana smoked is a strong predictor of negative health outcomes at 50-year-old
individuals.
Marijuana and the key outcome variables
The liver function test consists of testing the level of ALT, AST, the level of
ALT/AST ratio (LSR), TB, GGT, and LDH in a serum sample (Huang, et al., 2017).
Several other studies also introduced ALB, TP and ALP as part of the liver function test
(Fumeaux et al., 2018).
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ALT and Marijuana
ALT is a circulating transaminase in the human body and a specific marker for
liver dysfunction (Huang et al., 2017). The enzyme activity is influenced by clinical
factors including hepatitis-related diseases, alcohol consumption, disease states such as
NAFLD, and certain medications and physiological factors such as extreme physical
exertion (Z. Liu, Que, Xu, & Peng, 2014). Socio-demographic factors such as age,
gender, and ethnicity may also interfere with the enzyme activity (Kim et al., 2017; Ruhl
& Everhart, 2012). Although the enzyme is measured to assess overall health (Z. Liu et
al.,2014), the elevated level is often observed in liver dysfunction meaning that the
enzyme is more specific to liver disease (Marshall et al., 2014). Per Mohamed et al.
(2015) chronic marijuana use is associated with the hepatic enzymatic alteration.
Mohamed et al. (2015) conducted a case-control study of 60 people with a history of
cannabis use and 60 samples in a control group. Age and sex were matched with age
ranging from 18 to 60 years old. The study excluded people with liver cirrhosis, hepatitis,
jaundice, hepatomegaly, and liver carcinoma and found a significant statistical difference
in ALT between the two groups. The study concluded that cannabinoids are possible
hepatotoxic substances. By contrast, Kotan et al. (2017) found a normal ALT level (mean
28.4, SD 18.9, normal ALT < 45) in 118 Indians male cannabis users who used cannabis
for more than 30 months. In cannabis-dependent users, Quraishi et al. (2013) also found
that, although it is difficult to solely isolate cannabis-dependent subjects, cannabisdependent with co-morbid substance use showed an elevated ALT level in 51 subjects
with a 17.6% increase compared to the control group. Contrary to its toxicity effect
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presented in non-liver disease patients, cannabis may have a therapeutic effect by
normalizing the level of ALT in NAFLD (Kim et al., 2017). In a cross-sectional study,
Kim et al. (2017) found a statistically significant difference in ALT levels between
current cannabis users and past users and those individuals who never used cannabis who
are suffering from NAFLD. Heavy cannabis users with NAFLD showed a normal low
ALT level (28.0 SD 2.0, p < 0.001) compared to light users (30.5 SD 0.8, p < 0.001). A
significant statistical difference has also been seen in the ALT levels across gender
between current, and past users and those who never used presenting with NAFLD.
AST and Marijuana
Like ALT, the serum level of AST also increases during liver dysfunction.
However, AST is less specific to the liver compared to ALT. Apart from being elevated
in liver diseases, the activity of the enzyme is also influenced by the state of particular
disease such as in myocardial infarction, muscular dystrophy, pulmonary emboli, and in
acute pancreatitis (Marshall et al., 2014).
Demographic factors such as age, gender and ethnicity are also important when
evaluating the activity of AST (Kim et al., 2017; Ruhl & Everhart, 2012). It is also
known that marijuana alters the effect of AST (Mohamed et al., 2015). Mohamed et al.
(2015) elucidated in a case-control study involving 60 subjects that the AST level in
marijuana users is significantly different compared to the control group in a Sudanese
population. The study then concluded that a possible alteration effect of marijuana on
AST exists. Contrary to the above finding, Kotan et al. (2017) discovered a normal level
of AST (31.2, SD 22.0, Normal AST < 37) in 118 Indians male cannabis users who used
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cannabis for more than 30 months. In another case-control study, Quraishi et al. (2013)
found that cannabis dependent users with comorbid substance use had elevated AST
activity with 33.33% of the study subjects showing abnormal values of AST. By contrast,
Rahmayanti et al. (2017) revealed that most of the patients who used cannabis and other
drug exhibited normal AST levels. The study evaluated cannabis use with comorbid drug
users in more than 823,810 cases with more than 50% using cannabis and found that most
of the subjects (88.83%) displayed within normal range serum AST level. Only 1.12% of
participants showed below normal range AST level, and 11.6% of the participants
displayed AST levels that are above the normal range. Other studies like the one
conducted by Muniyappa et al. (2013) found no effect of cannabis on AST. In a crosssectional, case-control study, involving 30 cannabis smokers (12 women, 18 men,
Average age = 27 years, SD 8 ) and 30 control subjects matched for age, sex, ethnicity
and BMI, Muniyappa et al. (2013) found no statistical difference between the AST of
cannabis smokers and nonsmokers (control group).
ALP and Marijuana
ALP is another enzyme used as part of liver function tests to evaluate possible
dysfunction of the liver (Bishop et al., 2018; Lowe & John, 2018). A non-specific
enzyme, 80% of ALP found in the serum originates from the liver and bones and in small
amounts from the intestine. In most adult patients, an elevated ALP is an indicator of
liver disease (Lowe & John, 2018). The clinical significance of ALP activity lies in the
diagnostic of cholestatic liver disease (Bishop et al., 2018). The enzyme serves as a
marker of extrahepatic cholestasis such as stone in the bile duct or intrahepatic
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cholestasis such as drug-induced cholestasis or biliary cirrhosis (Bishop et al., 2018;
Lowe & John, 2018; Sharma et al., 2014). However, the interpretation of ALP is difficult
because variation in the enzyme activity can occur in different liver conditions including
liver cirrhosis, chronic hepatitis, viral hepatitis and in the absence of liver damage such as
congestive heart failure, related bone disorders and in primary and metastatic cancer
(Bishop et al., 2018; Lowe & John, 2018). Age, gender, and ethnicity are demographic
factors associated with variations in ALP activity. The ALP level is slightly higher in
men compared to women, and it decreases in the 15 to 50 age group, then and increases
again in the old age (Lowe & John, 2018). A positive association has also been found
between ALP body weight and smoking (Bishop et al., 2018; Lowe & John, 2018).
Marijuana has been shown to be strongly correlated with an increase in ALP level in a
case-control study in the Sudanese population using 60 patients who used cannabis for
more than ten years matched with 60 controls non-smoker subjects. Chronic smokers
showed a significant increase in ALP compared to non-smokers (Mohamed et al., 2015).
A study conducted in India in 34 cannabis users (mean duration of cannabis use was 30.5
months; SD 31.8) showed normal ALP serum level (Mean ALP = 73.4, SD 30.0; ALP
normal < 136; Kotan et al., 2017). Contrary to the above finding, Quraishi et al. (2013)
found a significant increase in ALP in cannabis-dependent subjects pointing to an
abnormality in liver function due to cannabis use. A total of 51 substance-using subjects
with a mean duration of cannabis use of 9.53 years (SD 8.06 years) and 30 control
subjects were used during the study. Findings revealed an elevation of 37.25% in
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substance-using subjects compared to the control group (control group 98.82, SD 26.46;
subjects’ group 217.53, SD 95.84., p < 0.05)
TB and Marijuana
Bilirubin is a breakdown of old and damaged red cells collected in the liver.
Sometimes the body can have an excess of bilirubin, a condition called
hyperbilirubinemia and recognized as jaundice (yellow discoloration of the skin, eyes and
mucous membranes) when the excess is accumulated in the tissue (Bishop et al., 2018).
Clinical conditions including liver disorders, liver infections such as hepatitis, cholestasis
and Gilbert syndrome may increase the level of bilirubin in human serum. However,
medications, such as phenobarbital and theophylline, contribute to lower levels of
bilirubin in the human body (Bishop et al., 2018; VanWagner & Green, 2015).
Bilirubin is part of a liver function test to evaluate a possible disorder of the liver
(Bishop, 2018). Factors other than liver disease may cause an increase in bilirubin. So, it
is important to know the etiology of the Jaundice, (VanWagner & Green, 2015; Bishop,
2018). In prehepatic jaundice such as in acute and chronic hemolytic anemia and posthepatic anemia including gallstones and tumors, the liver should be ruled out as the
primary cause of the increased level of bilirubin (Bishop, 2018). In hepatic jaundice, the
primary cause of elevated bilirubin is due to liver diseases or disorders related to bilirubin
metabolism and transport which are functions intrinsic to the liver (Bishop, 2018).
Among factors that increase the level of bilirubin, cannabis is a contributing factor. In
India, a case-control study involving 250 male subjects (125 cannabis abusers and 125
control group) found a significant difference in the mean value of TB when the two
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groups were compared. Cannabis abusers exhibited a TB value of 14.78 (SD 3.10)
compared to 11.1 (SD 3.23) in the control group (Wani et al., 2017). However, in a crosssectional study involving 34 cannabis users (Average age 21.8 years, SD 5.0; duration of
cannabis use 30.5 months, SD 31.8), Kotan et al. (2017) showed that cannabis users
presented a normal value TB levels (normal TB: 0.3- 1.2 mg/dl). By contrast, Quraishi et
al. (2013) found that the consumption of cannabis increases the level of serum bilirubin
by 13.72% compared to noncannabis users using a case-control study in 30 control
subjects and 51 cannabis dependent subjects (Average age of initiation 15.31 years, SD
4.7; duration of cannabis use 9.53 years SD 8.06).
TP and Marijuana
The serum TP, which is mainly synthesized by the liver, is of great importance
because it serves in the regulation of several physiological functions, maintaining the
osmotic pressure, transport of various metabolites, and participation in the activity of the
immune system (Bishop, 2018). The level of serum TP gradually decreases with age and
varies across gender (Tian, Qian, Shen, Li, & Wen, 2014). The evaluation of serum TP is
useful to assess the synthetic ability of the liver. Although the protein level is not a
sensitive marker for liver damage, its useful in quantifying the severity of liver
dysfunction (Bishop et al., 2018). Findings of the health effect of marijuana on the Total
serum protein in adults varies across studies. A case-control study conducted in India
which assessed the level of serum TP in 125 cannabis abusers, compared 125 noncannabis smokers and found a decreased level of serum TP in cannabis abuser compared
to non-smokers (Wani et al., 2017). Unlike the previous study, Quraishi et al. (2013)
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found in another case-control study involving 51 cannabis-dependent participants and 30
control subjects that smoking cannabis increased the level of serum TP by 15.68%.
ALB and Marijuana
Synthesized by the liver, albumin is the major type of protein in human serum. It's
involved in maintaining proper osmotic pressure and in the transport of various
substances through the body (Bishop et al., 2018; Morman & Varacallo, 2018). A low
concentration of albumin is most commonly associated with potential liver disease
(Morman & Varacallo, 2018). Illegal drug use such as cannabis has been shown to
decrease the level of albumin in human serum. In a recent case-control study, Quraishi et
al. (2013) demonstrated the presence of a low albumin level in cannabis dependent
patients compared to non-users with a mean duration of cannabis use being 9.53 years
and the mean age of initiation being 15.31 years. Like the previous study, Wani et al.
(2017) also found a lower score of albumin level in cannabis users compared to nonusers. In a different cohort, with age of initiation 21.8 years and the duration of cannabis
use being 30.5 months, Kotan et al. (2017) found a normal level of albumin in 34
participants with average ALB level of 4.20g/dl (SD 0.6, normal range 3.5-5.2g/dl).
GGT and Marijuana
Elevated activity of GGT is found in liver dysfunction, hepatobiliary disorders
and chronic alcohol consumption (Koenig & Seneff, 2015; Bishop., 2018). Drugs such as
warfarin, phenobarbital, and phenytoin are noted to increase the enzyme level. Marijuana
consumption is also noted to affect the level of GGT. Wani et al. (2017) noted in a casecontrol study of 250 male participants (125 cannabis abusers and 125 control group,
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mean age 25.32 years) that cannabis abusers exhibited a higher level of GGT compared
to non-users. However, 34 participants with a mean age of 21.8 years who use cannabis
for 30.5 months (SD 31.8), exhibited a normal level of GGT of an average 24.6 (SD 13.1,
Normal range < 55 u/l; Kotan et al., 2017).
Summary of the Literature Review
Four major factors are at the core of the increasing health problems associated
with marijuana, including: (1) increasing decriminalization of the drug, (2) decrease in
perceived risks seen in young male subjects, (3) increase in potency of illegal marijuana
from 4 to 12% in recent years, and (4) the increased prevalence of marijuana
consumption, which has more than doubled in recent years. Despite these four core
issues, epidemiological study findings of the health effects of marijuana are conflicting.
Several studies reported the therapeutic effect of the drug with respect to certain diseases,
while others are still warning about its adverse health effects and have recommended
more epidemiological investigations.
It is important to point out that in this literature review, the health effect of
marijuana on the liver has been more studied on individuals with preexisting liver
conditions including NAFLD, NASH, and hepatitis-C. The available literature on the
effect of marijuana on the liver of healthy participants is rare.
Finally, several studies have shown that the quantity of marijuana smoked, the age
of initiation and the duration of marijuana use are critical factors in assessing the health
effects of marijuana on the liver. These studies revealed that marijuana consumption
causes some variations in the enzymatic activity of the liver.
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Chapter 3: Research Method
This chapter provides explanation for the different steps in the data analysis
process from the data collection to the testing of the above hypotheses. I explain the
rationale of the epidemiological design chosen to guide the study, the sampling
procedure, the data collection procedure, and how the variables were measured and
coded. Finally, Chapter 3 presents the data analysis plan, which includes a procedure for
how the dataset was cleaned to make it appropriate to analyze and how the hypotheses
were tested. The data analysis plan gives an overview of all assumptions necessary to use
Linear regression analysis to test the hypotheses
Study Design and Rationale
Study designs are key factors needed to appropriately address the study questions.
Choosing an inappropriate study design has the potential to undermine the study validity,
which is critical in determining the scientific value of any effective research study
(Munnangi & Boktor, 2018). Thorough planning and accurate identification of study
factors and study subjects are important in selecting an adequate study design (Szklo &
Nieto, 2014). The goal of this section is to explain the ground on which a cross-sectional
study design is chosen to elucidate the study questions and how it is to be applied to
answer the study questions. In addition, the advantages and disadvantages of using a
cross-sectional study design in the context of the project are also presented. To
understand the relation between the disease factors and specific behavior in group of
people, or the cause of diseases, or the disease patterns, epidemiologic scholars
established specific epidemiologic study designs that helps to appropriately address
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possible questions during epidemiological events (Friis & Sellers, 2009; Munnangi &
Boktor, 2018; Szklo & Nieto, 2014).
As stated previously, I designed this study to evaluate the predictors of the health
effects of marijuana on the hepatic function. The study addresses the question of whether
the dose of marijuana use, the age of initiation of marijuana use, and the duration of use
are associated with liver dysfunction. Three independents variables, seven dependent
variables, and four controlled variables were manipulated to answer the study questions.
The independent variables included the number of joints or pipes smoked daily, the age
of initiation, and the duration of marijuana use. The dependent variables were the liver
function parameters, which comprise the serum level of ALT, AST, ALB, ALP, TB, TP,
and the GGT. The four controlled variables were the age of the participants, their gender,
the average alcohol consumed daily and the BMI of the participants.
An effective study design depends on the intent of the investigator, the unit of
analysis and the time dimension (Friis & Sellers, 2009; Szklo & Nieto, 2014). For
instance, if the investigator is willing to control the exposure of interest, the best option to
address study questions is to opt for experimental study design. Otherwise, the
observational study design is more appropriate (Friis & Sellers, 2009). In an experimental
study design, the investigator has control over the research setting and randomly assign
subjects to the exposed and non-exposed group (Friis & Sellers, 2009). Contrary to the
experimental study design, in an observational study, the investigator has no control over
the circumstances in the research setting and does not control the exposure of interest or
manipulate the study subjects (Friis & Sellers, 2009; Munnangi & Boktor, 2018; Szklo &
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Nieto, 2014). The observational study design moves closer to the cross-sectional study
design. Depending on the unit of analysis and the temporal dimension of the study, an
observational study design can be subcategorized into a cohort study, case-control study
and a cross-sectional study (Babby, 2017; Munnangi & Boktor, 2018). In all three study
designs, the exposure is measured at the individual level. In cross-sectional study designs,
the exposure and disease are measured at the individual level at a single point of time
(Friis & Sellers, 2009; Munnangi & Boktor, 2018, Szklo & Nieto, 2014). Cross-sectional
studies, used to assess the prevalence of the disease in a population, do not require a
follow-up period and cannot provide a cause-and-effect relationship (Munnangi &
Boktor, 2018).
The dataset used in this study was self-reported data, which includes exposure and
outcome information at an individual level at a specific point of time. For that reason, it
was more appropriate, in the case of these types of data to explore a cross-sectional study
design to answer the study questions. Furthermore, the intent of this study was not to
establish a cause-and-effect relationship but to assess a possible association between
predictors of the health effects of marijuana and hepatic function. Correlation data
analysis is an appropriate tool to evaluate such an association. According to Lau (2017),
the correlational study can be used to determine the prevalence and to predict future
events based on known data. A correlational study is more concerned about establishing a
relationship between exposure and outcome variables without any attempt to influence
them (Asamoah, 2014; Lau, 2017). In correlational studies, researchers need to identify
the study variables, establish study questions and hypotheses, select appropriate sample
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and data, calculate correlation, and finally report and interpret results (Asamoah, 2014;
Lau, 2017). In this study, the variables, the study questions, the hypothesis, and the data
source have already been mentioned. However, the statistical technique that allowed
establishing possible correlation has not yet been adequately addressed.
This study, I used statistical techniques to test the hypotheses that answered the
study questions. The choice of statistical techniques that adequately answered the study
questions depended on the sample size, the type of research questions being asked, and
the scale of measurement (Nayak & Hazra, 2011). The choice of linear regression to test
the hypotheses in this study was based on two major factors. First, the goal was to
establish a relationship between two or more variables, and secondly, the outcome
variables were continuous variables. Assuming that all other assumptions were met, the
two factors mentioned above were sufficient to adequately use linear regression. In this
context, data were collected using multistage sampling techniques. So, instead of using a
standard multiple regression, a complex sample general linear model (CSGLM) was used
in SPSS to analyze the data. The CSGLM procedure performs linear regression analysis,
as well as analysis of variance and covariance, for samples drawn by complex sampling
methods (International Business Machines [IBM], 2017)
Stated simply, this study was an observational cross-sectional study by nature,
which used a linear regression model to test the hypotheses. It is important to note that
the study can only suggest that there is a relationship between two or more variables, it
cannot imply causality.
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Multiple Linear Regression
The regression model is important to describe the relationship between an
outcome variable and one or more independent variables (Hosmer et al., 2013). Linear
regression is used for that same purpose. It allows to prediction of variability in an
outcome variable based on other variables (Kutner, 2004) However, linear regression
differs from other regression models as it examines the association between one or more
independent variable that are continuous or categorical and one continuous outcome
variable (Kutner, 2004). The model follows the equation
=

+

+

+⋯+

Where: Y is the expected value of the independent variable
x1 through xi are i distinct independent or predictor variables
b0 is the value of Y when all of the independent variables (x1 through xi)
are equal to zero
b1 through bi are the estimated regression coefficients
Each estimate regression coefficient represents the change in the dependent
variable for a one-unit change in the corresponding independent variable, holding all
other independent variable constant (Kutner, 2004).
Methodology
The Study Population
The study population was drawn from the NHANES data from 2009 to 2016 data
cycles. The NHANES contains health data from representative U.S. residents, or more
specifically, the civilian noninstitutionalized U.S. population. The survey comprised
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household sample screening, interviews, and physical examinations (NCHS, 2015b).
Although the NHANES contains data on all health-related issues and all ages, I drew the
sample for this study from participants aged 20 to 59 years old who have had contact with
marijuana or hashish. I excluded the population sample with a history of HBV and HCV
infections.
The NHANES relied on questionnaires and examination surveys to select and
collect data on the target population. For the present study, questionnaires related to the
age of the participants, the age at which the participants first tried marijuana or hashish ,
the time since the participants last used marijuana, the number of joints or pipes the
participants use in a day, and how often the participants use marijuana were critical in
compiling the study sample. Liver function test results performed in the laboratory on
participant's blood samples during the physical examination process were also part of the
study sample. These laboratory tests included the blood serum level of ALT, AST, ALB,
TP, TB, ALP, and GGT.
Sampling and Sampling Procedures
The NHANES, conducted by NCHS at the Centers for Disease Control and
Prevention (CDC) gathered health information on the U.S. noninstitutionalized
population including the U.S. 50 states and the District of Columbia. The survey
excluded people in custody in an institutional setting, all active-duty military personnel,
active-duty family members living overseas, and all other U.S. citizens living outside of
the U.S. (Johnson, Dohrmann, Burt & Mohadjer, 2014).
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Established in 1970, the NHANES has evolved since 1999 to become a
continuous health data collection program that collects data and releases data on a twoyear cycle (NCHS, 2015a). The survey consists of a household screening, an interview
process, and a physical examination at a medical examination center (MEC; Johnson,
Dohrmann, Burt, & Mohadjer, 2014). The household screen determines if the household
is eligible for an interview and a physical examination. The interview process collects
person-level data on demographic factors, health, and nutrition information as well as
household information. The third step that includes a physical examination helps to
collect data on the participant's blood pressure, dental health status, and to collect blood
samples for laboratory testing (Johnson et al., 2014). The NHANES gathered the health
data through a complex multistage probability sampling design. The first stage is
selecting the Primary Sampling Units (PSU) from all counties in the U.S. (NCHS,
2015b). In some cases, due to sample size requirements, some small counties or adjacent
counties may be combined (Johnson et al., 2014). The second stage consists of selecting
area segments comprising census blocks or combinations of census blocks containing
cluster of households designed to produced equal sample size per PSU. (NCHS, 2015b).
The third stage consists of selecting specific households and dormitories within each
segment. The fourth stage consists of selecting persons in each sampled household.
(Johnson et al., 2014). The NHANES oversampled some specific race, age, sex, and
income subgroups to increase the precision rate (NCHS, 2015a; Johnson et al., 2014). For
example, in the latest NHANES (2015-2016), Hispanic persons, non-Hispanic black
persons, non-Hispanic Asian persons; non-Hispanic white and other persons who
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reported race other than black, Asian or white aged 80 years and older and persons below
185% of the U.S. Department of Health and Human Services (HHS) guidelines were
oversampled (NCHS, 2015a). Every year, the expected annual sample size is 6888
persons with 5000 participants expected to have the physical examination (Johnson et al.,
2014). In the 2015-2016 survey cycle, the latest data cycle released, 15,327 persons were
selected for NHANES from 30 different survey locations. Of those selected, 9,971
completed the interview and 9,544 were examined (NCHS, 2015b).
For the current study, the sample was compiled from the NHANES data from the
2009-2010 survey cycle to the 2015-2016 survey cycle which is a combination of 4
survey cycles over eight years of data collection. As part of this study, the sample
selection was based on the participants who answered the drug questionnaire: “have you
ever used marijuana or hashish.” All participants who were 20 -59 years old, males or
females, who answered “YES” to the drug-using questionnaires were included in the
study. However, to reduce bias, I applied some exclusion criteria. Only the participants
who used marijuana or hashish within the last 30 days of the survey were included and,
people with severe hepatitis B and C disease were excluded from the study.
Sample Size Justification
Software such as G*Power, and SPSS sample power are available to evaluate the
minimum sample size required to obtain acceptable power for a study validation.
Although this software make the calculation of minimum sample size easy and less time
consuming, multiple regression using the G*Power to determine the actual sample size
required the R2 (percentage of variability in the outcome variable that is explained by the
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predictor variables). At this point in the study, these required data are not yet available.
However, G*Power offers a priori calculation of the sample size base on the anticipated
effect size, the desired statistical power and the number of predictors and an estimated R2
of .5.
In this study, the calculation of the minimum sample size using the F-statistical
test for multiple linear regression (Fixed model, R2 deviation from zero) in G*Power
yielded a sample size of 153. It’s important to note that the calculation was performed
following the established guideline of G*Power 3.1.7 (Faul et al., 2013) with alpha 0.05,
a power of 0.95, and a medium effect size of 0.15 and R2 of .5. for three predictor
variables. A posthoc analysis of sample size was performed when data became available.
Data Collection Procedures
Started in 1960, the NHANES was designed to access the health status of the
American people of all ages with various health conditions (NCHS, 2015a). From 1999,
the survey started collecting data continuously and included nutritional risk factors as part
of its inquiries (NCHS, 2015a). Each year, the survey sampled more than 5000
participants located in different counties across the United States (Johnson et al., 2014).
Using the multistage sampling process to identify potential candidates, the survey
followed three steps. The prescreening process helped to identify if a household qualifies
for the interview process. The interviews were carried out at the participant's home by
trained health professionals using the Computer-Assisted Personal Interview (CAPI) on
questions related to sociodemographic, dietary health, and general health is a very
delicate part of NHANES operations (NCHS, 2015b). The interviews were followed by a
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physical examination at the MEC. Three MEC are often active in a given time in the U.S.
which were designed to cover the 15 counties selected during any survey period (NCHS,
2015a). During the examination surveys, on top of conducting a dental, medical,
physiological examinations and laboratory tests, the health professionals also gather data
on the prevalence of chronic conditions on the participants. Data on risk factors
associated with the participant's lifestyles, environmental factors, and hereditary
conditions are also collected. Cigarette and tobacco smoking, alcohol consumption, drug
use status, sexual practice, physical activities, reproductive health, contraception,
breastfeeding practice, weight, and dietary intake data are also collected during the
medical examinations (NCHS, 2015a).
The local health and government officials in an upcoming survey area are notified
ahead of the survey. The participants receive letters from the director of the NCHS to
introduce the survey (NCHS, 2015a). To increase and facilitate participation, the
NHANES provide transportation to and from the MEC. Participants also receive
compensation and a report of the medical examination findings. The Unique feature of
the NHANES compared to other surveys in the US is the collection of the medical
examination data on each participant. For that reason, the operation at the MEC is
carefully designed (NCHS, 2015a). An average of approximately 450 persons are
examined in each of the 15 locations during every survey cycle. To minimize cost and
increase the response rate, the survey is set up to sample a larger number of persons
within a selected household (NCHS, 2015a).
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The NHANES data have been used in several instances to develop and monitor
nutrition and health programs across the US. research organizations, universities, and
health care providers. Health educators benefited from the NHANES data to study key
health issues, monitor and develop health programs, implement awareness programs and
reduce health-related risk factors (NCHS, 2015a). The NHANES data have been key
factors in establishing a growth chart that was used nationally by pediatricians. The data
have also been instrumental in the implementation of policy that contributed to the
reduction of the level of lead in food and canned soft drinks (NCHS, 2015a). The trend in
overweight prevalence, policy, and related programs and awareness were initially linked
to NHANES data. National programs to reduce hypertension, cholesterol and
undiagnosed diabetes have found their root in the NHANES data (Division of Nutrition,
Physical Activity, and Obesity, 2014).
Gaining Access to the Data
The NHANES data were available at no cost on the CDC’s website. All related
documentations, including questionnaires, physical examinations, laboratory protocols,
recommendations on analytical techniques were also available. The data were available in
SAS format and need to be exported in the appropriate software format.
Variables Operationalization, Measurement, and Coding
Independent variables.
Number of joints or pipes of marijuana use daily was measured using the
responses to the question “During the time you smoked marijuana or hashish, how many
joints or pipes would you usually smoke in a day?” The answers were collected on a scale
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of 1 per day, 2 per day, 3-5 per day, and 6 or more per day. The term marijuana included
all forms of the drugs known as pot or grass either smoked as a cigarette (joints) or in a
pipe or cooked. Hashish is a form of marijuana known as “hash” or hash oil. For analysis
purposes, the categories 1 per day, 2 per day, 3-5 per day, and 6 or more per day were
used as defined.
Age of initiation was measured using the responses to the question “How old were
you when you started smoking marijuana or hashish at least once a month for one year?
The answer to this question is known in NHANES as the age at which the participants
started regularly smoking marijuana. In regard to this study, the age of initiation was the
age at which someone started and continued regularly using marijuana. I relied on the
recommended age categorization from the United Nations (UN) which was categorized
into five groups, including under 15, 15-24, 25-44, 45-64, and 65+ (UN, 1982). For this
study, I recoded the above categories into three categories, including teen (under 15 years
old), youth (15 to 24 years old), and adult (25 to 59 years old).
Duration of marijuana use is the period in a lifetime when marijuana was used.
The duration of marijuana used was calculated by subtracting the age since marijuana
was last used from the current participant age. To account for only current users, I
excluded any participants who had not used marijuana during the last 30 days from the
analysis. The calculation of the duration of marijuana use also assumed that the
participants continuously used marijuana since their time of the first contact. The age
since marijuana was last used was measured in the NHANES by asking the question
“How long has it been since you last smoked marijuana or hashish at least once a month
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for one year?”. For this study, I categorized the duration of marijuana use into five
groups: under 10 years, 10 to 19 years, 20 to 29 years, 30 to 39 years, and greater than 40
years.
Dependent variables.
ALT levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling ALT levels were tested on approved calibrated
instruments. The normal range for ALT expressed in international units per liter (IU/L)
for males and females aged 20 years and older was 11 to 47 IU/L and 7- 30 IU/L
respectively.
AST levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling, AST levels were tested on approved calibrated
instruments. The normal range for AST expressed in international units per liter (IU/L)
for males and females aged 20 years and older was 13 to 33.
ALB levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling, ALB levels were tested on approved calibrated
instruments. The normal range for ALB expressed in gram per deciliter published by
NHANES for males and females aged 18 years and older was 3.7 to 4.7 g/dL.
ALP levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
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appropriate storage and handling ALP levels were tested on approved calibrated
instruments. The normal range for ALP expressed in international units per liter
published by NHANES for males and females aged 18 years and older was 36 to 113
IU/L.
TB levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling TB levels were tested on approved calibrated
instruments. The normal range for TB expressed in milligrams per deciliter (mg/dL)
published by NHANES for males and females aged 18 years and older was 0.2 to 1.3
mg/dL.
TP levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling, TP levels were tested on approved calibrated
instruments. The normal range for TP expressed in grams per deciliter (g/dL) published
by NHANES for males and females aged 18 years and older was 6.4 to 7.7 mg/dL.
GGT levels were determined using laboratory standard testing methods. Collected
plasma and serum samples were sent to the approved laboratory for testing. After
appropriate storage and handling, GGT levels were tested on approved calibrated
instruments. The normal range for GGT expressed in International Units per Liter (IU/L)
published by NHANES for males and females aged 18 years and older was 10 to 65 IU/L
and 8 to 36 U/L respectively.
Control variables.
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Alcohol use was measured through the question “In the past 12 months, on those
days that you drank alcoholic beverages, on average, how many drinks did you have?”
One drink was defined as 12 oz of beer, 5 oz of wine, or 1.5 oz of liquor with one
alcoholic drink equivalent to any beverage containing 14 g of pure alcohol (Office of
Disease Prevention and Health Promotion [ODPHP], n. d.). Following the dietary
guidelines for the year 2015-2020, I categorized alcohol consumption into light drinkers
(less than 2 drink per day), moderate drinkers (2 to 4 drinks per day) and heavy drinkers
(4 or more drinks per day).
BMI is a calculation of the weight in kilograms divided by the height in meter
squared. The weight and height were measured during the examination survey. The BMI
was categorized following the guidelines recommended by the National Heart, Lung, and
blood Institute (NHLBI, n.d.) where less than 18.5 was defined as underweight; between
18.5 and 24.9 as normal weight; 25 to 24.9 as overweight; and 30 or greater as obese.
Age: In the context of this study, age refers to the age of the participants at the
date of screening.
Gender: In this study, the gender of the participants can be male or female.
Data Analysis Plan
I used the IBM SPPS statistic version 25 to analyze the data. The NHANES data
was initially published in SAS software format. The SPSS 25 was used to import the data
into the SPPS software format for analysis.
I based the interpretations of the results on the p value, the value of the R2, the B
coefficient (the slope coefficient) and the 95% confidence interval (95% CI). The B
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coefficient represents the change in the dependent variable for a one-unit change in the
independent variable while all other independent variables are kept constant (Laerd
statistics, 2015). The B coefficient needs to be statistically significant to be included in
the equation. R-squared (R2) is the proportion of variance in the dependent variable that is
accounted for by the independent variables (Laerd statistic, 2015).
Data Cleaning and Screening
Missing values. The presence of missing values in a dataset compromises the
reliability of the study and leads to smaller sample size (Kwak & Kim, 2017). To obtain
adequate data for analysis, and to avoid selection bias, I exclude all cases that had one or
more missing values. I applied a listwise deletion technique in SPSS for a complete-case
analysis.
Outliers. The presence of outliers in a sample data introduce bias that may lead to
underestimation or overestimation of statistical results. Both univariate and multivariate
outliers must be assessed and removed from the data sample to reduce possible bias
(Kwak & Kim, 2017). I applied winsorization function and the Mahalanobis distance
function in SPSS to identify, assess and reduce the effect of univariate outliers and
multivariate outliers. The winsorization consists of replacing the value of the outlier that
is being tested with an expected value, the largest of the second smallest value in the
observation (Kwak & Kim, 2017). The Mahalanobis distance function is used to assess
and reduce the effect of multivariate outliers.
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In this study, I assessed the following research question and hypotheses and
conducted a statistical analysis to evaluate the predictor of the health effects of marijuana
on hepatic function:
Research question: Is there any significant association between the number of
joints or pipes of marijuana smoked in a day, the age of initiation, the duration of use and
each of the serum level of liver function markers including the serum levels of ALT,
AST, ALB, ALP, TB, TP, and GGT while controlling for the age of participants, their
gender, the average alcohol use and BMI?
H01: There is no significant association between the number of joints of marijuana
smoked in a day, the age of initiation, the duration of use and each of the serum level of
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and
GGT while controlling for the age of participants, their gender, the average alcohol use
and BMI.
H11: There is significant association between the number of joints of marijuana
smoked in a day, the age of initiation, the duration of use and each of the serum level of
liver function markers including the serum levels of ALT, AST, ALB, ALP, TB, TP, and
GGT while controlling for the age of participants, their gender, the average alcohol use
and BMI.
As stated earlier, I used CSGLM to analyze the data. For validity and inference
purposes, linear regression requires that the dataset meets some basic assumptions. For
instance, the outcome variable must be continuous, and one or more of the independent
variables (s) must be measured either on a continuous or nominal scale. Furthermore, the

62
dependent variables and all independent variables must be mutually exclusive (Osborne,
2015). Other major assumptions that the dataset must meet to consider using linear
regression as an appropriate statistical tool to test the hypotheses include the assumption
of linearity, the assumption of normality, the assumption of no multicollinearity, the
assumption of homoscedasticity and the assumption of no significant outlier, no high
leverage points or no highly influential points (Osborne, 2015).
Major Assumptions of Linear Regression
Assumption of Linearity
In linear regression, the independent variables need to be linearly related to the
dependent variable (Laerd statistic, 2015; Osborne, 2015). However, when in the
presence of more than one independent variable, the independent variables collectively
need to be linearly related to the dependent variable (Laerd statistic, 2015) . In this study,
a scatterplot of the studentized residuals (SRE) against the (unstandardized) predicted
values was used to evaluate the presence or lack of linearity. The assumption of linearity
is met if the pattern of a scatterplot allows the presence of a straight line. Otherwise, the
data is said to fail the assumption of linearity.
Assumption of Lack of Multicollinearity
Multicollinearity is basically due to the presence of a high correlation between
one or more of the independent variables. Multicollinearity makes it difficult to identify
which independent variable causes the variation in the dependent variable (Leard statistic,
2015). In this study, two values, the Tolerance (TOL) value and the variance inflation
factor (VIF) value were used to assess the collinearity. A TOL of less than 0.10 or a VIF
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greater than 10 implied the presence of collinearity (University of California, Los
Angeles [UCLA], n. d).
Assumption of Normality
For inferential purposes, the error in prediction also knows as the residual needs
to be normally distributed (Kutner et al., 2004). The normality was assessed in SPSS
using Normal Q-Q Plot of the studentized residuals which plot two sets of quantiles again
each other. The data is normally distributed if the scatterplot forms a straight line (Kutner
et al., 2004). If the data is extremely skewed, the normality of the distribution may not be
obtained. However, remediation techniques can be applied to obtain a normal distribution
of the data (Kutner et al., 2004; Laerd statistic, 2015).
The Assumption of Homoscedasticity
Homoscedasticity is a condition required in a linear regression analysis where
there are equal error variances for all values of the predicted independent variables.
Homoscedasticity is evaluated in SPSS by plotting the studentized residuals (SRE)
against the unstandardized predicted values (PRE). Homoscedasticity is present when the
spread of the residual shows a particular pattern.
Assumption of Independence of Observations
One of the major assumptions when using the least square method for regression
analysis is the lack of autocorrelation in the regression residuals (Kutner et al., 2004).
The presence of autocorrelation generates regression estimates that may not be effective
(Kutner et al., 2004). Autocorrelation in the residuals of the regression model has
traditionally been estimated using the Durbin-Watson (DW) statistic (Bazilevsky, 2018).
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I used SPSS command through the linear regression analysis to generate the DW values
in this study.
Assumption of No Significant Outliers, High Leverage Points, or Highly Influential
Points
As described earlier, I used the SPSS univariable outlier identification function to
assess univariates outliers and I also applied Mahalanobis distance evaluation technique
to identify and assess the effect of multivariate outliers. The leverage and the influential
point were measured using Cook's distance. Cook’s distance gives information on the
residual and the influential point (UCLA, n. d). The lowest value of the Cook’s distance
is zero, and the higher the Cook’s distance is, the more influential the point is. The cutoff
point of Cook’s distance is 4/n, where n is the number of observations (UCLA, n. d).
I conducted a descriptive statistical analysis to better understand of the dataset and
its different variations. The statistical description included assessing the mean, median,
mode, variance, the maximum and the minimum values, the skewness and the kurtosis of
each variable of the study population. I assessed the adequacy of the model and evaluated
the contribution of each independent variable to the model, and finally interpreted the
study results. During this study, I set the significance level (p-value) to 0.05 meaning that
the probability of rejecting a null hypothesis when it was true is 0.05.
Validity of the Study
Portino (2018) defined the validity of a research study as to how well the results
of a study on a sample of a population represent a true finding of that population outside
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the limit of the study. Portino distinguished two types of validity: internal and external
validity
Internal Validity
Internal validity examines the extent to which a study was designed, conducted,
analyzed to allow a true result (Andrade, 2018). In brief, the internal validity refers to a
methodological error in a research study (Portino, 2018). For example, in the current
study, the internal validity can be threatened by how the participants were selected, how
the measurement scale was applied, error in recoding the data, consideration in minimum
sample size, error in data collection, inappropriate analytical plan and statistical tool
used, and how the results of the study were approached and interpreted. Many research
techniques were used to improve the internal validity of the current study. These
techniques included a careful selection of study participants, predetermine minimum
sample size, appropriate data cleaning, and screening. Furthermore, this study ensured
that an appropriate statistical tool was used with respect to all required assumptions.
Analytical plan and results interpretation followed the guidance of several statistical and
epidemiological manuals authored by Asamoah (2014), Lau (2017), Munnangi and
Boktor (2018), and Osborne (2015).
External Validity
External validity examines if the results of a study apply to a similar population in
a different setting or if the findings are generalizable to other study contexts (Portini,
2018; Andrade, 2018). For example, in this study, a good external validity means that the
findings apply to all 20 to 59 years old marijuana users in the US. Another factor that
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ensures validity in this research study is the weighting criteria initially applied to the
NHANES data that I intend to use. Weighting the data produces an estimate
representative of the general population parameters when the sampling population is
chosen with unequal probability (NCHS, 2015a). In the context of this study, weighting
criteria was applied during the analysis to take into consideration the multistage sampling
technique used during the NHANES survey. To ensure that the study had a good external
validity, participants were randomly selected from the population, and several statistical
adjustments were applied for the sample to be representative of the population.
Ethical Procedure
Data were accessed from the NHANES website. The NHANES data are public
data available to be downloaded online. Access to the data requires no permission from
the NHANES staffs. Data were completely de-identified and anonymous. The NHANES
protocol was developed and reviewed to comply with requirements for the protection of
human subjects in research. The policy required ethical treatment of all research subjects
including vulnerable populations (NCHS, 2015a). The protocol was continuously
reviewed and amended by the CDC’s Institutional Review Board (IRB). Every
participant received an inform consent which detailed the survey process and their right
as survey participants. Information on confidentiality and how their privacy is to be
protected was also given to the participants in the form of a brochure. Data related to the
current study were downloaded on an electronic storage device and kept in a safe place.
Data were uniquely used for this study and will be safely discarded 5 years after the
study.
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Summary

The above chapter gives an overview of the different steps in the data analysis
process from the data collection to the testing of the hypotheses. The rationale of the
epidemiological design chosen to guide the study, the sampling procedure, the data
collection procedure, and variables coding were all explained. The chapter also presents
the different assumptions testing procedures, the data analysis plan, the minimum sample
size identification procedure, and how the dataset was cleaned to make it appropriate to
analyze and test the hypotheses. Finally, this chapter presents the scope in which the
study is valid such as ensuring that an appropriate statistical tool is used, all required
assumptions are met, analytical plan and results interpretation followed the guidance of
statistical and epidemiological theories and that the results of the study apply to a similar
population in a different setting or the findings are generalizable to other study contexts.
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Chapter 4: Results
The purpose of this study was to use a cross-sectional analysis to identify the
health effects of three potential marijuana use predictors on hepatic function. The health
effects of the predictor variables associated with marijuana use such as the number of
joints or pipes of marijuana smoked daily, the age of initiation and the length of time
marijuana was used were examined. The study was designed to address one research
question, which was to evaluate if any association exist between the three predictor
variables and each of the biochemistry profile of the liver, including the serum level of
ALT, AST, ALB, ALP, TB, TP, and the GGT. This chapter is organized into three
sections. The first section addresses the data collection and manipulation for analysis, the
second section evaluates the different assumptions, and the final section presents and
discusses the study results.
Data Collection and Manipulation for Analysis
A combination of four survey cycles of data collected from 2009 to 2016 was
obtained from NHANES. A total of 40,439 cases were obtained. The dataset included
data from drug questionnaires and laboratory test results. Variables in the dataset
included basic demographic variables, such as the age of the participants, their gender,
and their race. The drug questionnaires included the age at which marijuana was first
tried, the age at which participants started regularly using marijuana, the time since
marijuana was last used, and the number of joints or pipes of marijuana used per day. The
laboratory data included data regarding the biochemistry profile of the liver, such as the
serum levels of ALT, AST, ALB, ALP, TB, TP, and GGT. The response rate for the
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NHANES varied from 79.4 and 77.3 for the interview and examination survey,
respectively, in the 2009-2010 survey cycle to 61.3 and 58.7 in the 2015-2016 survey
cycle, also respectively. Those in the study dataset only included participants who
attended both the interview and examination section of the survey and had used
marijuana during the last 30 days of the survey.
For analysis purposes and to reduce the risk of biased results due to the presence
of missing values, all cases with one or more missing values were removed from the
initial dataset. The removal of the missing cases generated a final sample size of 702
participants. Figure 3 summarizes all exclusion criteria applied to the initial dataset and
showed the sample size at each step.
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Figure 3. Sample size and screening criteria.
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Data were transformed into different categories as indicated in Chapter 3. The
number of joints or pipes of marijuana used daily was categorized as 1, 2, 3-5, and 6 or
more per day. The age of initiation was categorized as teen (under 15 years old), youth
(15 to 24 years old), and adult (25 to 59 years old). The duration of marijuana use was
calculated and categorized into five groups: under 10 years, 10 to 19 years, 20 to 29
years, 30 to 39 years, and 40 and greater than 40 years. Alcohol consumption was
categorized into light drinkers (less than 2 drinks per day), moderate drinkers (2 to 4
drinks per day) and heavy drinkers (4 or more drinks per day). BMI was categorized
following the guidelines recommended by the NHLBI (n.d.) where less than 18.5 was
defined as underweight, between 18.5 to 24.9 as normal weight, 25 to 29.9 as overweight,
and 30 or greater as obese. The outcome variables, which comprised the biochemistry
profile of the liver were continuous variables and were taken as reported.
Results
Descriptive Statistics
The mean age for the participant sample was 37 years with 75% of them being 47
years old. Approximately, 63% of the participants were male, and 37% were female.
Non-Hispanic White participants accounted for 67.4% of the sample, while non-Hispanic
Black represented 14.2%, and, the remaining 18.4% was represented by American
Mexican, other Hispanic, and multiracial groups. On average, participants tried marijuana
for the first time at 16 years old, while they started using it regularly at 18 years old. The
number of joints or pipes used in a day was around two, with 75% of the participants
smoking three or fewer joints or pipes per day. Among marijuana users, 75% of the
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participants used marijuana within 13 days of the survey. Approximately, 29.3% of the
participants used marijuana for less than 10 years of their life, 26.3% used it for 10 to 19
years, 16.8% used it between 20 to 29 years, 23.8% used it for 30 to 39 years and 3.8%
used it for more than 40 years, which demonstrated that the length of use was agedependent.
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Table 1
Descriptive Statistics: Categorical Variables
Variables
Gender
Male

Percent (%)

Population size

63

5,255,757

37

3,083,015

7.1

588,479

Other Hispanic
Non-Hispanic White

5.1
67.4

429,147
5,620,662

Non-Hispanic Black

14.2

1,188,212

6.1

512,272

1 per day
2 per day

42.5
31.2

3,540,280
260,8815

3-5 per day
Six or more per day

20.8
5.5

1,735,156
454,521

26.7
64.9

2,228,084
5,413,327

Adult (25 - 59 yrs.)
Duration of use

8.4

697,361

Under 10 yrs.

29.3

2,446,015

10 to 19 yrs.
20 to 29 yrs.

26.3
16.8

2,190,251
1,403,711

30 to 40 yrs.
40 yrs. and greater

23.8
3.8

1,985,461
313,331

1.6

133,126

Normal weight

31.9

2,656,910

Overweight
Obese

35.9
30.7

2,990,771
2,557,965

Female
Race
Mexican American

Other race
Number of joints or pipes smoked/day

Age of initiation
Teen (<15 yrs.)
Youth (15 - 24 yrs.)

BMI
Underweight

Alcohol/day
Light drinker

39.1

3,257,070

Moderate drinker

35.1

2,927,236

Moderate drinker

25.8

2,154,466
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Table 2
Descriptive Statistics: Continuous Variables
95% CI

Age of participant
Age of initiation

Mean
37.2

Std Error
.63

Lower
35.9

Upper
38.5

Population
size
8,338,772

17.94

.23

17.46

18.41

8,338,772

ALB

4.36

.02

4.37

4.39

8,338,772

ALP

63.39

.90

61.53

65.26

8,338,772

AST

25.07

.55

23.92

26.22

8,338,772

ALT

25.58

.58

24.39

26.78

8,338,772

GGT

27.68

1.10

25.40

29.97

8,338,772

TB

.65

.02

.61

.68

8,338,772

TP

7.05

.030

6.99

7.11

8,338,772

Avg # alcoholic /day

3.80

.15

3.49

4.12

8,338,772

BMI

28.13

.22

27.67

28.60

8,338,772

Duration of use

19.29

.53

18.19

20.38

8,338,772

Preparing for Analysis
For analysis purposes, I evaluated the dataset for adequate sample size, missing
data and the normality of the distribution. I also examined the dataset for all required
assumptions to employ general linear regression analysis.
Post hoc analysis of sample size. Seven CSGLMs were employed in this study
corresponding to each of the outcome variables. Each of the CSGLMs yielded a different
R2 value used to calculate the required sample size. The R2 values obtained from the
CSGLM analysis ranged from .074 to .287 and achieved a power of 1.00. In short, with a
sample size of 702 participants and a medium effect size of .15 at alpha .05, a power
greater than 99% was achieved, which was enough to detect possible associations
between the variables.
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Assessing and addressing missing data. The missing data in the NHANES
survey are data that are completely unavailable due to participants non-response and
component non-response. The participants non-response occurred both at the interview
and the medical examination phases of the survey. Not all those who were interviewed
were selected to participate in the examination phase of the survey, thus creating missing
data in the examination phase of the survey. The component non-response was related to
situation where persons who were selected to participant in the medical examination
phase of the survey did not fully participate in a component of the examination. For
example, there were individuals who agreed to have their blood drawn but did not get
their blood pressure taken, thus creating a missing value in the data set. A third situation
that added to the number of the missing values was when the participants refused to
answer a particular question or answered ‘unknown’. These values were coded in the
NHANES as 7, 77, 777 or 9, 99, 999 depending on the number of digits in the variable
value range. In this study, I also coded these values as missing.
I used the missing values pattern under the multiple imputations function in SPSS
to assess the pattern of missing data. Overall, the dataset had eight cases of missing data
with 99% of complete cases.

76

Figure 4. Summary of missing data.
According to the analytical guideline provided by the NHANES, if 10% or less of
data for the main outcome variable for a specific component is missing it is acceptable to
continue analysis without further evaluation or adjustment. In this study, there was less
than 1% of missing cases, and consequently, a listwise deletion technique was applied to
the dataset and all cases with one or more missing values were removed.
Analysis of Assumptions
Assumption of independence of observations.
One of the major assumptions when using the least square method for regression
analysis is the lack of autocorrelation in the regression residuals (Kutner et al., 2004).
The presence of autocorrelation generates regression estimates that may not be effective.
Autocorrelation in the residuals of the regression model has traditionally been estimated
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using the Durbin-Watson (DW) statistic (Bazilevsky, 2018). In this study, I used the
Durbin-Watson test to evaluate possible autocorrelation between the independent
variables. The test command is available as an option through the multiple linear
regression procedure in SPSS. The following table presents the values of DW obtained
when each of the multiple regression analysis was performed for each outcome variable.
Table 3
Durbin-Watson Test Results Per Regression Analysis
ALT

AST

ALB

ALP

TB

TP

Durbin-Watson 1.899

2.070

2.005

1.948

2.022

1.984

GGT
1.996

The DW statistic ranged in values from 0 to 4 (Kutner et al., 2004). However, as a
rule of thumb, a value of 2 indicates that there is no correlation between residuals (Laerd
Statistics, 2015). In conclusion, after contrasting the values in the above table and the rule
of thumb, the independence of observations as required for linear regression analysis was
met.
Assumption of multicollinearity Evaluation.
In multiple regression, there must be no correlation between the predictor
variables (Kutner et al., 2004). Multicollinearity was evaluated through the linear
regression analysis in SPSS which offers collinearity diagnostic. I obtained two values to
test for the collinearity, the Tolerance (TOL) and the variance inflation factor (VIF)
values. The TOL is an indication of the percent of the variance in the predictor that
cannot be accounted for by the other predictors (UCLA, n. d). The VIF is the reciprocal
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of the TOL value. A TOL of less than 0.10 (i.e. a VIF greater than 10) implied the
presence of collinearity (UCLA, n.d.).
Table 4
TOL &VIF Values Per Regression Analysis
ALT
Tol

VIF

AST
TOL

VIF

ALB
TOL

VIF

ALP
TOL

VIF

TB
TOL

TP
VIF

TOL

GGT
VIF

TOL

VIF

Gender

.934 1.071

.933 1.072

.934 1.071

.932 1.074

.932 1.074

.932 1.074

.934 1.071

Age in
years
# Joints/day

.103 9.716

.05617.935

.103 9.716

.05318.961

.05318.961

.05318.961

.103 9.716

.909 1.100

.913 1.096

.909 1.100

.907 1.102

.907 1.102

.907 1.102

.909 1.100

Age of
initiation
Duration of
use
BMI

.521 1.919

.05518.220

.101 9.922

.953 1.049

.953 1.049

.953 1.049

.953 1.049

.101 9.922

.954 1.048

.953 1.049

.924 1.082

.924 1.082

.924 1.082

.924 1.083

.953 1.049

.923 1.083

.924 1.083

.343 2.918

.343 2.918

.343 2.918

.521 1.919

Alcohol/day

.924 1.083

.279 3.584

.521 1.919

.05119.493

.05119.493

.05119.493

.101 9.922

After conducting an analysis, it appeared that multicollinearity existed in the
dataset. The control variable age of the participants was correlated to the predictor
variable “age of initiation” as well as to the variable “alcohol consumed” while the
regression was performed with respective outcome variable AST, ALP, TB and TP.
Kutner et al. (2004) advised that the simplest way to remedy the problem of
multicollinearity is to drop one of the offending variables, although it might affect the
regression estimates and the R2 values. As a result, the age of participant variable was
dropped from the analysis where multicollinearities were observed.
Assumption of normality Evaluation.
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An initial evaluation of the adequacy of the data for linear regression showed
histograms of the standardized residuals that appeared to be extremely positively skewed,
thus generating normality curves that significantly departed from the expected normality.
According to Laerd Statistic (2015), possible remediation of a variable that is not
showing normality is to transform the variable. In this study, all outcome variables were
transformed except for ALB and TP by computing the reciprocal of their data. The
following figures showed the normality curves before and after the transformations were
conducted.
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Normality curve for AST before and after transformation
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Normality curves for ALT before and after transformation
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Normality curve for ALB. No transformation needed
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Normality curves for ALP before and after transformation
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Normality curves for TB before and after transformation

Normality curve for TP. No transformation needed
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Normality curves for GGT before and after transformation
Figure 5. Normality curves.
The assumption of normality has then been satisfied after the outcome variables
were transformed.
Assumption of homoscedasticity evaluation.
A major assumption required to apply the least squares regression model is that
the variance is equal for all values of the predicted dependent variable (Kutner et al.,
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2004). I evaluated the assumption of homoscedasticity by plotting the studentized
residuals against the unstandardized predicted values. The scatterplots of the different
multiple regression analyses were shown below. Homoscedasticity is present when the
spread of the residual shows a particular pattern. In each of the scatterplot below, a
pattern was not observed. The assumption of homoscedasticity has been met.

Homoscedasticity scatterplot with ALT as the dependent variable

Homoscedasticity scatterplot with AST as the dependent variable
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Homoscedasticity scatterplot with ALB as the dependent variable

Homoscedasticity scatterplot with ALP as the dependent variable
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Homoscedasticity scatterplot with TB as the dependent variable

Homoscedasticity scatterplot with TP as the dependent variable
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Homoscedasticity scatterplot with GGT as dependent variable
Figure 6. Homoscedasticity scatterplots.
Assumption of linearity Evaluation.
A least squares regression analysis required a linear relationship between the
dependent and independent variables collectively and between the dependent and each of
the independent variables (Kutner, et al., 2004; Laerd Statistics, 2015). The scatterplots
of the studentized residuals against the unstandardized predicted values obtained above
for the homoscedasticity evaluation were also used to evaluate the collective linearity
between the predictors and outcome variables. The observation of the scatterplots showed
that there was a linear relationship between the predictors and the outcome variables.
The linearity was also evaluated for the relationship between each independent variable
and the outcome variable. The patterns of scatterplots obtained appeared to be showing
linearity. As a conclusion, the assumption of linearity has been met.
Outlier’s Assessment.
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Outliers are extreme observations. According to Kutner et al. (2004), in the
regression model, it is difficult to identify outliers by simple graphical means. When in
the presence of more than one or two predictors variables, a multivariable outlier’s
analysis may be necessary. In multiple regression analysis, some univariate outliers may
not be extreme, and, conversely, some multivariable outliers may not be detectable in
single-variable or two-variable analysis (Kutner et al., 2004). In this study, I used the
Mahalanobis distance function in SPSS to detect multivariate outliers. I identify three
outlying cases. To ascertain whether the identified outlier cases were influential, I
estimated Cook’s distance value for each of them. Cook’s distance combines information
on residual and Leverage (Kutner et al., 2004). The higher the Cook’s distance, the more
influential is the outlying point. The conventional cut-off for the Cook’s distance is (k
+1)/n where k is the number of independent variables in the model, and n is the number
of observations.
In the context of this study, the three outliers that were identified had Cook’s distance
values that were less than .005 (4/702), which was the cut-off for Cook’s distance in the
study. Although the three cases were identified as outliers, they were not influential in the
regression analysis. Consequently, these three cases were kept in the dataset for analysis.
Research Question Analysis
I analyzed the research question by performing seven different CSGLM analyses,
with each different liver enzyme as the outcome variable. I based the interpretations of
the results on the p value, the value of the R2, the B coefficient (the slope coefficient) and
the 95% confidence interval (95% CI). A parameter was said to contribute to the model,
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and the null hypothesis rejected if the p value is less than .05 and the 95% CI does not
include 0. In any other case, a failure to reject the null hypothesis meant that the
parameter failed to contribute to the model with a p value greater than .05 and a 95% CI
includes 0.
During the presentation of the results, the “mean model” was often used. The
mean model is the model without any predictor variable, it is simply the mean of the
dependent variable (Laerd Statistics, 2015).
Part 1 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the number of joints or
pipes of marijuana use and the serum levels of ALT while controlling for age, gender,
alcohol use, and BMI?
To analyze the effect of the three predictor variables on ALT, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the number of joints of marijuana use as predictor variables,
while the control variables were age, gender, alcohol consumption, and the BMI. ALT
was used in the regression analysis as the outcome variable. The model revealed a p value
less than .0005 which satisfied p < .05 with an R2 value of .237, suggesting that the
presence of all the independent variables produced a model that statistically significantly
predicted the dependent variable and provided a better fit to the data than the mean
model. An R2 value of .237 means that the presence of all predictor and control variables
in the regression model explained 23.7% of the variability observed in ALT.
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Table 5
Test of Model Effects with ALT as the Outcome Variable
Source

df1

df2

Wald F

Sig.

(Corrected Model)

16.000

6.000

142.117

.000

(Intercept)

1.000

21.000

32.055

.000

Gender

1.000

21.000

60.170

.000

# of joints/day

3.000

19.000

.424

.738

Avg # Alcohol

2.000

20.000

4.107

.032

BMI

3.000

19.000

27.482

.000

Age of initiation

2.000

20.000

1.075

.360

Duration of use

4.000

18.000

.536

.711

Age of participant
1.000
21.000
.158
.695
a. Model: ALT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation +
Duration of use + Age at screening

Based on the analysis of results presented in the above table, the effect of the age
of initiation of marijuana on ALT revealed a p value greater than the cut off value of .05,
F(2, 20) = 1.075, p > .05, and the duration of use also showed a p value greater than .05,
F(4, 18) = .536, p > .05,. Finally, the effect of the number of joints of marijuana also
showed a p value greater than .05, F(3, 19) = .424, p > .05. These results suggest that the
three predictors failed to be statistically significant predictors of the effect of marijuana
use on ALT. In this case, the null hypothesis, which stated that there is no significant
association between the age of initiation, the dose of marijuana consumed, and the
duration of use of marijuana, and ALT failed to be rejected.
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Table 6
Parameter Estimates with ALT as the Outcome Variable
95% CI
Parameter

Estimate Std. Error

(Intercept)

Lower

Hypothesis Test

Upper

t

df

Sig

.041

.017

.005

.076

2.391 21.000

.026

Male

-.014

.002

-.018

-.010

-7.757 21.000

.000

Female

.000b

.

.

.

1 joints/day

-.003

.003

-.008

2 joints/day

-.001

.002

3-5 joints/day

-.002

6 or more joints/day

.000b

.

.

.

.003

-1.093 21.000

.287

-.006

.003

-.625 21.000

.539

.003

-.008

.004

-.590 21.000

.562

.

.

.

.003

.002

-.001

Moderate drink (2-4 drinks / day)

-.002

.003

Heavy drink (>= 4 drinks per day)

.000b

.

.

.007

1.736 21.000

.097

-.007

.004

-.584 21.000

.566

.

.

.

.012

.007

-.002

.014

.002

.002
.000b

Initiation as Teen (< 15 yrs old)
Initiation as Youth (15 – 24 yrs old)

Light drink (< 2 drink / day)

.

.

.

.026

1.831 21.000

.081

.010

.017

7.479 21.000

.000

.002

-.002

.006

1.075 21.000

.294

.

.

.

.004

.004

-.004

.001

.004

.000b

< 10 yrs. of use

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

.

.

.

.011

.935 21.000

.360

-.008

.010

.303 21.000

.765

.

.

.

.013

.009

-.006

10 to 19 yrs. of use

.011

.008

20 to 29 of use

.007

30 to 39 yrs. of use

Initiation as Adult (25 – 59 years old)

>40 yrs. of use

.

.

.

.032

1.411 21.000

.173

-.005

.027

1.420 21.000

.170

.006

-.006

.021

1.129 21.000

.271

.006

.006

-.006

.018

1.062 21.000

.301

b

.

.

.

.000

.

.

.

.

Age of participants
6.791E-5
.000
.000
.000
.397 21.000 .695
a. Model: ALT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration
of use
b. Reference category

The analysis of the results presented in the above table revealed that the
coefficient estimates of the different categories of each of the three predictor variables,
the age of initiation, the duration of use and the quantity of use failed to be statistically
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significant. This result was normal considering that the null hypothesis failed to be
rejected.
Part 2 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the number of joints or
pipes of marijuana use and the serum levels of AST while controlling for gender, alcohol
use and BMI?
To analyze of the effects of the three predictor variables on AST, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables, while the
control variables were, gender, alcohol consumption, and the BMI. AST was used in the
regression analysis as the outcome variable. In this model, the age of the participants as a
control variable was dropped due to its correlation with another independent variable in
the model. The model revealed a significant p < .0005 which satisfied p < .05 with R2 of
.142, suggesting that the presence of all the independent variables produced a model that
statistically significantly predicted the dependent variable and provided a better fit to the
model than the mean model. An R2 value of .142 means that the presence of all predictor
and control variables in the regression model explained 14.2% of the variability observed
in AST.
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Table 7
Test of Model Effects with AST as the Outcome Variable
Source

df1

(Corrected Model)

df2

Wald F

Sig.

15.000

7.000

34.080

.000

1.000

21.000

1079.146

.000

1.000

21.000

46.490

.000

# of joints/day

3.000

19.000

1.189

.341

Avg # Alcohol

2.000

20.000

2.793

.085

BMI

3.000

19.000

4.023

.023

Age of initiation

2.000

20.000

.176

.840

Duration of use

4.000

18.000

2.781

.058

(Intercept)
Gender

a. Model: AST transformed = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of
initiation + Duration of use

Based on the analysis of the results presented in the above table, the three
predictor variables failed to be statistically significant predictors of the effects of
marijuana use on AST. Consequently, the three predictor variables did not contribute to
the variation in AST observed above. Here, the statistical significance level of the effects
of the age of initiation on AST exhibited a value of .840, F(2, 20) = .176, p > .05, while
the significance level of the dose of marijuana consumed on AST was at .341, F(3 19) =
1.189, p > .05. Finally, the third predictor variable, the duration of use, showed a
statistical significance level of .058, F(4, 18) = 2.781, p > .05. The independent effects of
all three predictor variables showed non-statistically significant p values suggesting that
the null hypothesis failed to be rejected.
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Table 8
Parameter Estimates with AST as the Outcome Variable
95% CI

Std.
Parameter

Estimate

(Intercept)

Error

Lower

Hypothesis Test

Upper

t

df

Sig

.043

.004

.034

.052 10.264

21.000

.000

Male

-.008

.001

-.010

-.006 -6.818

21.000

.000

Female

.000b

.

.

.

.

.

1 joints/day

-.002

.002

-.006

.002 -1.056

21.000

.303

2 joints/day

-.001

.002

-.006

.003

-.625

21.000

.539

.000

.002

-.004

.004

-.132

21.000

.896

.000b

.

.

.

.

.

.

.001

.001

-.001

.003 1.101

21.000

.283

Moderate drink (2-4 drinks / day)

-.002

.001

-.003

.000 -1.942

21.000

.066

Heavy drink (>= 4 drinks per day)

.000b

.

.

.

.

.

.

-.002

.004

-.010

.007

-.393

21.000

.698

.002

.001

-.001

.005 1.301

21.000

.207

-.001

.001

-.004

.002

-.861

21.000

.399

.000b

.

.

.

.

.

.

Initiation as Teen (< 15 yrs. old)

.001

.002

-.003

.004

.555

21.000

.585

Initiation as Youth (15 – 24 yrs. old)

.001

.002

-.003

.004

.394

21.000

.697

Initiation as Adult (25 – 59 yrs. old)

.000b

.

.

.

.

.

.

< 10 yrs. of use

.010

.004

.001

.018 2.462

21.000

.023

10 to 19 yrs. of use

.007

.004

-.001

.015 1.865

21.000

.076

20 to 29 yrs. of use

.007

.003

.000

.014 2.228

21.000

.037

30 to 39 yrs. of use

.006

.003

-.001

.013 1.722

21.000

.100

3-5 joints/day
6 or more joints/day
Light drink (< 2 drink / day)

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

.

b

>40 yrs. of use
.000
.
.
.
.
.
.
a. Model: AST transformed = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation
+ Duration of use
b. Reference category

The analysis of the above table showed that the coefficient estimates of the
different categories of the three predictor variables failed to be statistically significant,
which is normal when the null hypothesis failed to be rejected.
Part 3 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the number of joints or
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pipes of marijuana use and the serum levels of ALB while controlling for age, gender,
alcohol use and BMI?
To analyze the effects of the three predictor variables on ALB, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables while the
control variables were, age, gender, alcohol consumption, and the BMI. ALB was used in
the regression as the outcome variable. The model revealed a significant p < .0005 which
satisfied p < .05 with R2 of .194, suggesting that the presence of all the independent
variables produced a model that statistically significantly predicted the dependent
variable and provided a better fit for the data than the mean model. An R2 value of .194
means that the presence of all predictor and control variables in the regression model
explained 19.4% of the variability observed in ALB.
Table 9
Test of Model Effects with ALB as the Outcome Variable
Source
(Corrected Model)

df1

df2

Wald F

Sig.

16.000

6.000

20.489

.001

(Intercept)

1.000

21.000

388.836

.000

Gender

1.000

21.000

42.133

.000

# of joints/day

3.000

19.000

2.250

.116

Avg # Alcohol

2.000

20.000

1.927

.172

BMI

3.000

19.000

9.130

.001

Age of initiation

2.000

20.000

.040

.961

Duration of use

4.000

18.000

.507

.731

Age of participants

1.000

21.000

.053

.820

a. Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation +
Duration of use + age of participants
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Based on the results of the analysis presented in Table 8, the effect of the age of
initiation on the ALB revealed a p value greater than .05, F(2, 20) = .040, p > .05 and the
duration of use also showed a p value than was greater than .05, F(4, 18) = .507, p > .05.
Finally, the effect of the number of joints of marijuana use also showed a p value that was
higher than .05, F(3, 19) = 2.250, p > .05. These results suggest that the three predictors
failed to be statistically significant predictors of the effect of marijuana use on ALB. In
this case, the null hypothesis which stated that there is no significant association between
the age of initiation, the dose of marijuana consumed, and the duration of use on ALB
failed to be rejected.
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Table 10
Parameter Estimates with ALB as the Outcome Variable
95% CI

Std.
Parameter

Estimate Error

(Intercept)

Lower

Hypothesis Test

Upper

t

df

Sig

.245

.017

.210

.281 14.265

21.000

.000

Male

-.010

.002

-.014

-.007 -6.491

21.000

.000

Female

.000b

.

.

.

.

.

.

1 joints/day

.001

.003

-.005

.006

.221

21.000

.827

2 joints/day

.001

.003

-.005

.006

.239

21.000

.813

3-5 joints/day

.004

.002

-.001

.009

1.635

21.000

.117

.000b

.

.

.

.

.

.

.002

.002

-.002

.006

.959

21.000

.348

Moderate drink (2-4 drinks / day)

-.003

.002

-.007

.001 -1.493

21.000

.150

Heavy drink (>= 4 drinks per day)

.000b

.

.

.

.

.

-.024

.007

-.039

-.009 -3.381

21.000

.003

-.009

.002

-.013

-.005 -4.739

21.000

.000

-.008

.002

-.013

-.004 -3.944

21.000

.001

.000b

.

.

.

.

.

.

.000

.005

-.010

.010

-.088

21.000

.931

Initiation as Youth (15 – 24 yrs. old)

-.001

.004

-.009

.008

-.170

21.000

.867

Initiation as Adult (25 – 59 years old)

.000b

.

.

.

.

.

.

< 10 yrs. of use

-.006

.008

-.023

.011

-.698

21.000

.493

10 to 19 yrs. of use

-.005

.006

-.018

.008

-.790

21.000

.438

20 to 29 of use

-.004

.005

-.014

.006

-.784

21.000

.442

30 to 39 yrs. of use

-.004

.003

-.011

.003 -1.232

21.000

.232

b

.

.

.

.

Age of participants
6.347E-5
.000
-.001
.001
.230
21.000
a. Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of
initiation + Duration of use + age of participants
b. Reference category

.820

6 or more joints/day
Light drink (< 2 drink / day)

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

Initiation as Teen (< 15 yrs. old)

>40 yrs. of use

.000

.

.

.
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As shown in Table 9, the coefficient estimates of the different categories of the
three predictor variables failed to be statistically significant with each category showing a
p value greater than .05.
Part 4 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the number of joints of
marijuana use and the serum levels of ALP while controlling for gender, alcohol use and
BMI?
To analyze the effect of the three predictor variables on ALP, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables while the
control variables were, gender, alcohol consumption, and the BMI. ALP was used in the
regression analysis as the outcome variable. The model revealed a significant p < .0005
which satisfied p < .05 with R2 of .074, suggesting that the presence of all the independent
variables produced a model that statistically significantly predicted the dependent
variable and that the data was a better fit to the model than the mean model. An R2 value
of .074 means that the presence of all predictor and control variables into the regression
model explained 7.4% of the variability observed in ALP.
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Table 11
Test of Model Effects with ALP as the Outcome Variable
Source

df1

(Corrected Model)

df2

Wald F

Sig.

15.000

7.000

5.262

.017

(Intercept)

1.000

21.000

1516.742

.000

Gender

1.000

21.000

4.161

.054

# of joints/day

3.000

19.000

1.715

.198

Avg # Alcohol

2.000

20.000

.236

.792

BMI

3.000

19.000

3.354

.041

Age of initiation

2.000

20.000

2.572

.101

Duration of use

4.000

18.000

4.661

.009

Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation +
Duration of use

Based on the results of the analysis presented in of Table 10, the age of initiation
and the quantity of marijuana use failed to be statistically significant predictors of the
effect of marijuana use on ALP with respective p values of .101, F(2, 20) = 2.572, p >
.05, and .198, F( 3, 19) = 1.715, p > 0.05. However, the duration of use showed a
statistically significant p value level of .009, F(4, 18) = 4.661, p < .05, suggesting that the
duration of use significantly contributed to the variation in ALP observed above. The
analysis of the coefficient estimates in the next table shows coefficient estimates values
for each category of the duration of use that were not statistically significant except for
the category where participants used marijuana for 10 to 19 years. So, the duration of use
of marijuana was a statistically significant predictor of the effect of marijuana use on
ALP. In this case, the null hypothesis partially failed to be rejected for the age of
initiation of marijuana use and for the quantity of marijuana use, and the alternate
hypothesis involving the effect of duration of use on ALP was accepted, as the duration
of use significantly predicted variation on ALP.
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Table 12
Parameter Estimates with ALP as the Outcome Variable
95% CI

Std.
Parameter

Estimate

Error

Lower

(Intercept)

.014

.001

Male

-.001

.000

Female

.000b

.

.

1 joints/day

.002

.001

2 joints/day
3-5 joints/day

Hypothesis Test

Upper

df

.000

-2.040

21.000

.054

.

.

.

.

.000

.003

2.382

21.000

.027

.002

.001 -9.796E-5

.003

1.960

21.000

.063

.001

.001

.000

.003

1.889

21.000

.073

.000b

.

.

.

.

.

.

Light drink (< 2 drink / day)

.000

.001

-.001

.002

.659

21.000

.517

Moderate drink (2-4 drinks / day)

.000

.001

-.001

.002

.571

21.000

.574

Heavy drink (>= 4 drinks per day)

.000b

.

.

.

.

.

.

-.002

.002

-.005

.002

-.958

21.000

.349

.001

.000

.000

.002

1.667

21.000

.110

.001

.000

.000

.002

2.766

21.000

.012

.000b

.

.

.

.

.

.

Initiation as Teen (< 15 yrs. old)

.000

.001

-.002

.001

-.512

21.000

.614

Initiation as Youth (15 – 24 yrs. old)

.001

.001

-.001

.002

1.159

21.000

.259

Initiation as Adult (25 – 59 yrs. old)

.000b

.

.

.

.

.

.

< 10 yrs. of use

.001

.001

-.001

.003

.891

21.000

.383

10 to 19 yrs. of use

.002

.001

.000

.004

2.574

21.000

.018

20 to 29 of use

.000

.001

-.001

.002

.337

21.000

.740

30 to 39 yrs. of use

.000

.001

-.001

.002

.266

21.000

.793

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

b

.016 13.427

Sig

21.000

6 or more joints/day

.012

t

-.002 1.811E-5

>40 yrs. of use
.000
.
.
.
.
.
a. Model: ALP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation +
Duration of use + age of participants
b. Reference category

.
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In the above table, except for the estimates of the duration of use of marijuana
ranging from 10 to 19 years, estimates for other categories of the predictor variables were
not statistically significant. The estimate of the duration of use for people who used
marijuana for 10 to 19 years was 0.002, B= .002, p < 0.05, 95%CI [.000 - .004]. This
result meant that people who used marijuana for 10 to 19 years had a serum ALP value
that was .002 IU/dl greater those who used marijuana for more than 40 years. Clinically,
the difference observed was too close to zero, meaning that there was no difference in the
serum level of ALP between people who used marijuana for 10 to 19 years compared to
people who used it for more than 40 years.
Part 5 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the number of joints of
marijuana use and the serum levels of TB while controlling for gender, alcohol use and
BMI?
To analyze the effect of the three predictor variables on TB, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables, while the
control variables were gender, alcohol consumption, and the BMI. TB was used in the
regression analysis as the outcome variable. The model revealed a significant p < .0005
which satisfied p < .05 with an R2 value of .106, suggesting that the presence of all the
independent variables produced a model that statistically significantly predicted the
dependent variable and is a better fit to the data than the mean model. An R2 value of .106
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means that the presence of all predictor and control variables in the regression model
explained 10.6 % of the variability observed in TB.
Table 13
Test of Model Effects with TB as the Outcome Variable
Source
(Corrected Model)

df1
15.000

df2
7.000

Wald F
20.980

Sig.
.000

(Intercept)

1.000

21.000

152.623

.000

Gender

1.000

21.000

25.738

.000

# of joints/day

3.000

19.000

4.859

.011

Avg # Alcohol

2.000

20.000

.374

.692

BMI

3.000

19.000

3.007

.056

Age of initiation

2.000

20.000

1.462

.256

Duration of use

4.000

18.000

1.794

.174

Model: ALB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation +
Duration of use

As shown in Table 12, the statistical significance level of the quantity of
marijuana use was .011, F(3, 19) = 4.859, p < .05, the duration of use was .174, F(4, 18)
= 1.794, p > .05, and the age of initiation was .256, F(2, 20) = 1.462, p > .05. The p
values for the quantity of marijuana use was less than the cut-off value of .05. In
conclusion, the quantity of marijuana use was found to have a statistically significant
effect on TB. However, the age of initiation and the duration of use failed to have a
statistical effect on TB. Consequently, the null hypothesis was partially accepted for the
age of initiation and the duration of use, which means that there is no statistically
significant association between the age of initiation, the duration of use and TB. For the
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quantity of marijuana use, the null hypothesis was rejected, meaning that the study found
a statistically significant association between the quantity of marijuana use and TB.
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Table 14
Parameter Estimates with TB as the Outcome Variable
95% CI

Std.
Parameter

Estimate

(Intercept)

2.912

.394

2.093

3.732

7.388

21.000

.000

Male

-.544

.107

-.767

-.321

-5.073

21.000

.000

Female

.000b

.

.

.

.

.

.

1 joints/day

-.536

.173

-.896

-.175

-3.091

21.000

.006

2 joints/day

-.332

.187

-.722

.057

-1.773

21.000

.091

3-5 joints/day

-.274

.213

-.716

.168

-1.289

21.000

.211

6 or more joints/day

.000b

.

.

.

.

.

.

Light drink (< 2 drink / day)

-.025

.107

-.247

.198

-.231

21.000

.819

Moderate drink (2-4 drinks / day)

-.104

.117

-.348

.140

-.887

21.000

.385

Heavy drink (>= 4 drinks per day)

.000b

.

.

.

.

.

.

-.577

.368

-1.342

.188

-1.568

21.000

.132

-.310

.128

-.575

-.045

-2.431

21.000

.024

-.256

.111

-.486

-.026

-2.313

21.000

.031

.000b

.

.

.

.

.

.

.034

.170

-.320

.387

.199

21.000

.844

Initiation as Youth (15 – 24 yrs old)

-.184

.150

-.496

.128

-1.225

21.000

.234

Initiation as Adult (25 – 59 years old)

.000b

.

.

.

.

.

.

< 10 yrs. of use

.122

.218

-.331

.574

.558

21.000

.583

10 to 19 yrs. of use

.260

.141

-.034

.554

1.840

21.000

.080

20 to 29 of use

.048

.148

-.259

.355

.323

21.000

.750

-.025

.186

-.412

.363

-.133

21.000

.896

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

Initiation as Teen (< 15 yrs old)

30 to 39 yrs. of use

b

Error

Lower

Hypothesis Test

Upper

t

df

sig

>40 yrs. of use
.000
.
.
.
.
.
.
a. Model: TB = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of
use
b. Reference category
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The results of analysis presented in Table 13, showed that for the variable
quantity of use, only the category of participants who used 1 joint of marijuana per day
was statistically significant with a coefficient estimate value of -.536, B= -.536, p < 0.05,
95%CI [-.896, - .175]. This result meant that people who used 1 joint of marijuana per
day had a TB level that was .536 mg/dl less than that for those who smoked more than 6
joints per day, with 95% confident that the difference in TB was between .175 mg/dl and
.896 mg/dl.
Part 6 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the quantity of
marijuana use and the serum levels of TP while controlling for gender, alcohol use and
BMI?
To analyze the effect of the three predictor variables on TP, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables while the
control variables were, gender, alcohol consumption, and the BMI. TP was used in the
regression analysis as the outcome variable. The model revealed a significant p < .0005
which satisfied p < .05 with an R2 value of .078, suggesting that the presence of all the
independent variables produced a model that statistically significantly predicted the
dependent variable better than the mean model and was a better fit for the data. An
R2value of .077 meant that the presence of all predictor and control variables in the
regression model explained 7.7% of the variability in TP.
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Table 15
Test of Model Effects with TP as Outcome Variable
Source

df1

(Corrected Model)

df2

Wald F

Sig.

15.000

7.000

16.975

.000

(Intercept)

1.000

21.000

23338.468

.000

Gender

1.000

21.000

3.861

.063

# of joints/day

3.000

19.000

1.308

.301

Avg # Alcohol

2.000

20.000

1.276

.301

BMI

3.000

19.000

1.945

.157

Age of initiation

2.000

20.000

.050

.952

Duration of use
4.000
18.000
3.401
.031
Model: TP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of
use

From the analysis of the results of Table 13, the effect of the age of initiation on
the TP revealed p value greater than .05, F(2, 20) = .050, p > .05, and that of the quantity
of use also showed a p value that was greater than 0.05, F(3, 19) = 1.308, p > .05. Finally,
the effect of the duration of use of marijuana showed a p value of less than .05, F(4, 18)
= 3.401, p < .05. The preceding results suggest that two of the three predictor variables,
the age of initiation and the quantity of marijuana use failed to be statistically significant
predictors of the effect of marijuana use on TP. In this case, the null hypothesis partially
failed to be rejected for the age of initiation and the quantity of marijuana use while it
was rejected for the duration of use.
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Table 16
Parameter Estimates with TP as the Outcome Variable
95% CI

Std.

Lower

Hypothesis Test

Parameter

Estimate Error

Upper

(Intercept)

.150

.004

Male

-.002

.001

Female

.000b

.

.

.

1 joints/day

-9.854E-5

.002

-.004

.004

2 joints/day

-.002

.002

.000
.000b

.141

t

df

sig

.159 36.150 21.000

.000

-.004 9.952E-5 -1.965 21.000

.063

.

.

-.049 21.000

.962

-.005

.002 -1.008 21.000

.325

.002

-.004

.005

.935

.

.

.

.001

.001

Moderate drink (2-4 drinks / day)

-.001

Heavy drink (>= 4 drinks per day)

.000b

3-5 joints/day
6 or more joints/day
Light drink (< 2 drink / day)

.

.082 21.000
.

.

-.001

.002 1.057 21.000

.303

.001

-.003

.001 -1.089 21.000

.289

.

.

-.006

.003

.000

.

.

-.013

.000 -1.937 21.000

.066

.001

-.002

.003

.383 21.000

.706

.000

.001

-.002

.002

-.200 21.000

.843

.000b

.

.

.

Initiation as Teen (< 15 yrs. old)

.000

.002

-.004

Initiation as Youth (15 – 24 yrs. old)

.000

.002

Initiation as Adult (25 – 59 years old)

.000b

< 10 yrs. of use

Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

m 2)

m 2)

or greater)

.

.

.

.

.

.

.003

-.286 21.000

.778

-.004

.003

-.121 21.000

.905

.

.

.

-.008

.003

10 to 19 yrs. of use

-.005

20 to 29 of use
30 to 39 yrs. of use

.

.

-.013

-.003 -3.058 21.000

.006

.002

-.010

-.001 -2.331 21.000

.030

-.005

.002

-.009

.000 -2.192 21.000

.040

-.005

.003

-.010

.000 -1.915 21.000

.069

b

.

>40 yrs. of use
.000
.
.
.
.
.
.
a. Model: TP = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of
use
b. Reference category
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As shown in Table 16, the coefficient estimates of each category of the predictor
variables were not statistically significant except for the duration of use, where the
coefficient estimates of the categories of people who use marijuana for less than 10 years,
10 to 19 years and 20 to 29 years were all statistically significant with respective
coefficient estimates of -.008, B = -.008, p < .05, 95%CI[ -.013, -.003], -.005, B = -.005,
p < .05, 95%CI[-.010, -.001] and -.005, B = -.005, p < .05, 95%CI[-.009, .000]. These
result indicate that people who used marijuana for less than 10 years had a TP level that
was .008 mg/dl less than that of people who used marijuana for more than 40 years, and
people who used marijuana for 10 to 19 years had a TP level that was .005 mg/dl less
than that of those who used marijuana for more than 40 years. There was no difference in
the decreased amount of TP between people who used marijuana for 10 to 19 years and
20 to 29 years compared to those who used it for more than 40 years. Concisely, the
difference in TP levels observed for each category of duration of use was too close to
zero, indicating that the differences were not clinically significant. As a result, there was
no difference in the serum level of TP for someone who used marijuana for less than 10
years, 10 to 19 years, and 20 to 29 years compared to those who used the drug for more
than 40 years.
Part 7 of the research question. Is there a significant association between the
duration of marijuana use, the age of initiation of marijuana use, the quantity of
marijuana use and the serum levels of GGT while controlling for age, gender, alcohol
use, and BMI?
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To analyze the effect of the three predictor variables on GGT, I performed a
complex linear regression analysis in SPSS with the duration of marijuana use, the age of
initiation of marijuana use, the quantity of marijuana use as predictor variables while the
control variables were age, gender, alcohol consumption, and the BMI. TP was used in
the regression analysis as the outcome variable. The model revealed a significance with p
< .0005 which satisfied p < .05 with an R2 value of .287, suggesting that the presence of
all the independent variables produced a model that statistically significantly predicted
the dependent variable and provided a better fit for the data than the mean model. The R2
value of .287 meant that the presence of all predictors and control variables in the
regression model explained 28.7 of the variability in GGT.
Table 17
Test of Model Effects with GGT as the Outcome Variable
Source

df1

(Corrected Model)

df2

Wald F

Sig.

16.000

6.000

49.921

.000

(Intercept)

1.000

21.000

22.745

.000

Gender

1.000

21.000

117.066

.000

# of joints/day

3.000

19.000

.931

.445

Avg # Alcohol

2.000

20.000

19.181

.000

BMI

3.000

19.000

10.702

.000

Age of initiation

2.000

20.000

.409

.670

Duration of use

4.000

18.000

.989

.438

Age of participants
1.000
21.000
.586
.452
Model: GGT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration of
use + Age of participants

As shown in Table 16, the effect of the age of initiation on the GGT revealed a p
value greater than .05, F(2, 20) = .409, p > .05, and the duration of use also showed a p
value that was greater than .05, F(4, 18) = .989, p > .05. Finally, the effect of the
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quantity of use also showed a p value greater than .05, F(3, 19) = .931, p > .05. The
preceding results suggest that the three predictor variables failed to be statistically
significant predictors of the effect of marijuana used on GGT. In this case, the null
hypothesis which stated that there is no significant association between the age of
initiation, the dose of marijuana consumed, and the duration of use on GGT failed to be
rejected.
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Table 18
Parameter Estimates with GGT as Outcome Variable
95% CI

Std.
Parameter

Estimate

(Intercept)

Error

Lower

Hypothesis Test

Upper

t

sig

.061

.024

.011

Male

-.021

.002

-.024

Female

.000b

.

.

.

1 joints/day

-.006

.007

-.019

.008

-.869 21.000 .395

2 joints/day

-.005

.006

-.017

.007

-.894 21.000 .382

3-5 joints/day

-.003

.006

-.016

.010

-.503 21.000 .620

6 or more joints/day

.000b

.

.

.

.013

.003

.006

.019

4.214 21.000 .000

1.673E-5

.002

-.005

.005

.007 21.000 .995

.000b

.

.

.

.016

.013

-.012

.044

1.186 21.000 .249

.020

.003

.013

.027

5.849 21.000 .000

.009

.002

.004

.014

3.778 21.000 .001

.000b

.

.

.

Initiation as Teen (< 15 yrs. old)

-.002

.009

-.020

.015

-.283 21.000 .780

Initiation as Youth (15 – 24 yrs. old)

-.003

.007

-.019

.012

-.438 21.000 .666

Initiation as Adult (25 – 59 years old)

.000b

.

.

.

< 10 yrs. of use

.017

.012

-.008

.043

1.413 21.000 .172

10 to 19 yrs. of use

.008

.010

-.013

.029

.785 21.000 .441

20 to 29 of use

.007

.009

-.013

.026

.699 21.000 .492

30 to 39 yrs. of use

.006

.008

-.010

.022

.744 21.000 .465

b

.

.

.

Light drink (< 2 drink / day)
Moderate drink (2-4 drinks / day)
Heavy drink (>= 4 drinks per day)
Underweight (< 18.5 kg/

m 2)

Normal weight (18.5 – 24.9 kg/
Overweight (25 – 29.9 kg/
Obese (30 kg/

m2

>40 yrs. of use

m 2)

m 2)

or greater)

.000

.111

df

2.556 21.000 .018

-.017 -10.820 21.000 .000
.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

.

Age of participants
.000
.000
-.001
.000
-.766 21.000 .452
a. Model: GGT = (Intercept) + Gender + # of joints /day + Avg # Alcohol + BMI + Age of initiation + Duration
of use
b. Reference category

Based on the results presented Table 18, the estimates of each category of the
three predictor variables were not statistically significant.
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Summary
The study was designed to address one research question, which was to evaluate if
any association exist between the three predictor variables and each of the biochemistry
profile of the liver, including the serum level of ALT, AST, ALB, ALP, TB, TP, and the
GGT. After ensuring that the dataset was adequate and met all required assumptions to
use linear regression to test the hypotheses, the results of the analysis revealed that the
age of initiation failed to be a significant predictor of the health effect of marijuana on all
the liver function markers, while the duration of use significantly predicted variations in
ALP and TP and the quantity of marijuana use was a predictors of the variation in TB
with an apparent detrimental effect on the serum level of TB level.
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Chapter 5: Discussion, Conclusions, and Recommendations
The scope of this study was to identify possible predictors of the health effects of
marijuana on hepatic function. The primary objective was to assess potential associations
between the number of joints or pipes of marijuana use, the age of initiation and the
duration for which marijuana was used with each of the serum levels of liver enzymes
including the serum level of ALT, AST, ALB, ALP, TB, TP and GGT using a large
nationally representative sample from the NHANES. Results of the analysis, revealed
that the age of initiation failed to be a significant predictor of the health effect of
marijuana on all the liver function markers, while the duration of use significantly
predicted variations in ALP and TP and the quantity of marijuana use was a predictors of
the variation in TB.
Interpretation of the Findings
Findings related to the health effect of marijuana on the liver are not consistent.
Studies revealed toxicological and therapeutic health effects on the liver associated with
marijuana use (Adejumo et al., 2018; Kim et al., 2017; McElrath et al., 2017). The
findings from prior studies were obtained in many cases from patients with preexisting
liver conditions where there was a possible lack of assessment of the health effects of the
predictors on individual liver enzymes. It is important to note that abnormal levels of the
individual liver enzymes are characteristic of different liver diseases, and thus
investigating the variation of these enzymes individually is very crucial. Furthermore,
many scholars, such as Wolkow et al. (2014), have reported that long-term use of
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marijuana may have detrimental health effects on the liver in a manner similar to the use
of alcohol and tobacco.
The Quantity of Marijuana Smoked and the Serum Level of Liver Enzymes
The findings in this study revealed that the amount of marijuana use is not a
statistically significant predictor of the health effects of marijuana on the hepatic enzymes
except for TB. According to this study, people who used 1 joint (or pipe) of marijuana
per day had a serum TB level that was .536 mg/dl less than that in people who used 6 or
more joints (or pipes) per day. In other words, heavy marijuana smokers tended to have a
higher level of serum TB compared to light smokers. This result is consistent with a casecontrol study in India that involved 250 male subjects (125 cannabis abusers and 125 in
the control group), where a significant difference was found in the mean value of TB
when the two groups were compared. Cannabis abusers exhibited a total bilirubin value
of 14.78 (SD = 3.10) compared to 11.1 (SD = 3.23) in the control group (Wani et al.,
2017). Similarly, Quraishi et al. (2013) found that the consumption of cannabis increases
the level of serum bilirubin by 13.72% compared to noncannabis users in a case-control
study of 30 control subjects and 51 cannabis dependent subjects (mean age of initiation =
15.31 yrs., SD = 4.7 yrs., duration of cannabis use = 9.53 yrs., SD 8.06 yrs.). In addition,
Borini et al. (2004) observed that there was no correlation between the amount of
marijuana use and the serum level of ALT, AST, ALP and GGT, which is also consistent
with this study’s results. No speculation was made regarding the association between the
quantity of marijuana use and the serum level of ALB, TB and TP in Borini et al.’s study.

117
Contrary to the findings in this study, other researchers found that the use of marijuana
has no detrimental effect on TB (Kotan et al., 2017).
The quantity of marijuana used is at the core of the discussions regarding the
predictors of the effects of marijuana on human health. Several studies associated the
quantity of marijuana use with a lower prevalence of disease and even therapeutic effect
to the drug (Adejumo et al., 2017; Donghee et al., 2017). The results of the current study
appeared to contradict these findings. It is apparent that elevated consumption of the drug
is associated with increased level of TB, which is known to be associated with hemolytic
jaundice, internal hemorrhage, and acute hemolytic anemia (Bishop et al., 2018).
Duration of Use and the Serum Levels of Liver Enzymes
The findings in the current study revealed that the duration of marijuana use is a
statistically significant predictor of the serum level of ALP and TP in marijuana users but
failed to be a predictor of the variation in the serum levels of ALT, AST, ALB, TP, and
GGT. Although there was a significant effect of the duration of use on ALP and TP, there
was no clinically significant difference in the serum level of ALP and TP when someone
who had used the drug for less than 10 years was compared to someone who had used it
for more than 40 years. Several studies have shown that the duration of marijuana use is a
possible predictor of the health effect of marijuana use of the liver. For example, Quraishi
et al. (2013) found that using cannabis for more than 9.53 years (SD = 8.06) had
detrimental health effects on the liver, while Kotan et al. (2017) found that there were no
health effects when cannabis was used for 30.5 months. It is apparent that the longer
marijuana is used, the more significant health effects it appears to have. In the current
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study, the average duration of marijuana use was 19.20 years (SD = 11.68). Still, the
effect of the duration of use was only significant on ALP and TP levels with no
difference in the level of ALP and TP among the users was found. The above results
suggested the need to introduce other epidemiological factors that may improve the
association between the duration of marijuana use and the level of liver enzymes. It has
been well known that aging factors, gender, and ethnicity have possible effects on the
activity of the liver enzymes (Bishop, 2018; Kim et al., 2017; Ruhl & Everhart, 2012;
Tian et al., 2014). In the present study, the impact of the age of the participants has not
been adjusted due to its correlation with other independent variables in the regression
equation. However, the regression equation in this study has been adjusted for gender, for
ALP, and for TP. The introduction of gender into the regression slightly modified the R2
value but had no significant effect on the coefficient estimates. Although the results of
the current study have not been consistent with respect to whether the duration of use has
a detrimental or therapeutic effect on the liver, it is essential to note that any imbalance
caused by the consumption of marijuana on TP and ALP is significant. Serum total
protein, which is mainly synthesized by the liver, is particularly important because it
serves in the regulation of several physiological functions, maintaining the osmotic
pressure, transport of various metabolites, and participation in the activity of the immune
system (Bishop, 2018). As for ALP, variation in the enzyme activity can occur in
different liver conditions, including liver cirrhosis, chronic hepatitis, and viral hepatitis,
and in the absence of liver damage such as congestive heart failure, related bone
disorders and in primary and metastatic cancer (Bishop et al., 2018; Lowe & John, 2018)
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The Age of Initiation and the Serum Levels of Liver Enzymes
The findings of the current study revealed that the age of initiation is not a
statistically significant predictor of the health effect of marijuana on liver enzymes. These
findings contradicted results from other studies (Quraishi et al., 2013) that indicated the
age of initiation is a possible predictor of the variations observed in the liver-related
health parameters. Kotan et al. (2017), for example, found that the age of initiation was a
significant predictor of the variations in liver enzymes.
The discrepancy observed in this study compared to other epidemiological studies
may be evidence of the variations in the age and gender of participants across study
samples. As much as the effects of age and gender factors were reduced in this study, the
impact of other potential confounders such as growth factors, nutrition factors, hormone,
injury factors, and diseases related factors could not be reduced. These factors were all
known to be contributing factors associated with the variations in levels of liver enzymes.
Limitations of the Study
The major strength of this study was that a large, nationally representative sample
was used. A combination of four survey cycles collected from 2009 to 2015 increased the
sample size and made it more appropriate for inference purposes. I excluded patients with
HBV and HCV infection, which have been found to increase liver enzyme levels. The
participants’ ages were limited to 20 to 59 years old to reduce the effect of aging factors
known to have a possible effect on observed variations in liver enzymes. Although, the
inclusion of a control group which in this case should be the non-marijuana users may
greatly strengthen the ability to draw conclusions from a study (Godby, 2018), I did not
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consider including control group in this study. Self-reported data are known to be a
source to bias. In the data sample used for this study, several steps including
oversampling of the minority population were taken to reduce selection bias. Although
the study was adjusted for some epidemiological factors such as age and gender, many
other epidemiological factors, including for example, income level, education level, and
lifestyle, would have contributed to the variations in liver enzymes and improved the
relationship between the variables. The study was only adjusted for the effect of BMI.
However, the effect of several metabolic factors including glucose and cholesterol, which
had been found to affect the function of the liver, could have been adjusted for a more
specific relationship between the predictors and outcome variables. Although excluding
HBV and HCV infected participants from the study may have contributed to reducing the
selection bias, other disease states, such as liver cirrhosis and liver cancer are known to
affect the level of liver enzymes (Bishop, 2018). Participants with these diseases have not
been excluded or the effect of these diseases have not been controlled due to the
unavailability of pertinent data. Several therapeutic drugs, such as phenobarbital and
theophylline, have also been found to affect the enzymatic level of the liver (Bishop et
al., 2018; VanWagner & Green, 2015). Data on these therapeutic drugs were not also
available to analyze their impact on the level of liver enzymes in the current study.
It would be interesting to investigate those who use other illicit drugs separately
from those who use only marijuana to ascertain whether there is a specific relationship
between the variables. Separating marijuana users from users of other illicit drugs has not
been investigated in this study, and it is also important to note that several authors have
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reported on the difficulties in doing so. The statistical methodology applied in this study
relied on linear regression analysis, which used the least square technique to analyze the
data. Many other statistical techniques exist, and their application to the current study
might be more appropriate to enhance the findings to the study. The results of the current
study were obtained based on hypotheses generated during the study using self-reported
data and interpretations of the results are limited to the context of this study. However,
alternative interpretations could not be completely ruled out.
Recommendations
This study used a large nationally representative sample to evaluate the health
effects of three predictor variables, including the quantity of marijuana use, the length of
time it was used, and the age of initiation, on the level of individual liver enzymes in a
healthy population. The findings revealed a significant effect of the quantity of marijuana
smoked on TB, while the duration of use was a statistically significant predictor for levels
of ALP and TP. The age of initiation failed to predict variations in any of the liver
enzymes. The study could be improved if marijuana users can be isolated from those
individuals who use other illicit drugs. It is well known that risk factors associated with
marijuana abuse include the concurrent use of other illicit drugs (Palamar et al., 2015). In
addition, illicit use of drugs such as cocaine can lead to several liver abnormalities,
ranging from mild asymptomatic elevation in liver enzymes to severe liver injury (Pateria
et al., 2013). Consequently, other illicit drugs are potential confounders in the association
of marijuana use with the liver, thus reducing the effects of these potential confounders to
obtain a clear association between marijuana uses and the liver become very important.
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There is evidence that the pattern and the effects of marijuana use are related to
race and ethnicity. For example, Pacek et al. (2012) found that marijuana use disorder
was greatest among African Americans compared to other race/ethnicities. In this study
sample, 67.4% of participants were non-Hispanic white. As a result, the study did not
consider a large proportion of the population who use marijuana. More studies with
different proportions of racial/ethnicities groups as well as studies in the minorities black
and Hispanic groups are needed to identify if the pattern of marijuana use in relation to
race and ethnicity is a defining factor in the relationship between marijuana use and liver
enzymes. The activities of the enzymes in the human body are complex and affected by
disease stages, lifestyle, nutritional status, and metabolic factors. Thus, they are potential
confounders in the relationship between marijuana use and the liver. Designing studies
that can adjust for these factors in a preexisting liver disease population and in a healthy
population sample is also needed. As observed in this study, the quantity of marijuana use
has effect on the activity of TB. However, this study is observational by design. There is
a need for experimental studies to quantify the amount of marijuana that is clinically
significant to affect the activity of the TB.
Implications for Social Change
The results of this study can be used for social change on two significant levels,
both to improve care management for marijuana users and to improve liver transplant
denial policy for marijuana users.
It is not uncommon in the medical diagnostic process to eliminate possible
illnesses or causes of disease one at a time using clinical information, history and lifestyle
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of the patient (Committee on Diagnostic Error in Health Care, 2015). Knowing exactly
the effect of marijuana on the liver enzymes will probably accelerate the process in
marijuana users and help in accurate diagnosis.
Despite the inconsistencies in the findings regarding the health effects of
marijuana on the liver, it remains a schedule I drug in the United States. Furthermore,
marijuana users are routinely denied liver transplants. Like other studies, the current
study also revealed that marijuana does not affect all liver enzymes. Accordingly, this
study adds to the existing literature to help review, or if necessary, to improve the liver
transplant denial policy for marijuana users.
Conclusions
Several studies have evaluated the effects of marijuana use on the liver by
comparing the prevalence of liver diseases in marijuana users and nonusers or by
comparing the quantity and the duration of marijuana use in people with preexisting liver
conditions. In this study, the effects of the drug on the individual liver enzymes was
evaluated in a healthy population. The study revealed that the length of time marijuana
was used is a possible predictor of variations in serum levels of ALP and TP although, no
significant difference has been observed in the level of ALP and TP in relation to whether
marijuana was used for 10, 20, 30 years compared to those who use it for more than 40
years. The quantity of marijuana used has also been revealed as a significant predictor of
variations in the serum level of TB with an apparent detrimental effect on the serum level
of TB level. Finally, the age of initiation has been found to have no significant effect on
the variations in the serum levels of liver enzymes.
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The current study used a nationally representative sample and applied linear
regression to evaluate hypotheses generated during the study. However, the data on
marijuana utilization were self-reported, and therefore it may include bias. Several
epidemiological, physiological and metabolic factors that are known to affect the
activities of the liver enzymes could have been controlled during analysis to reduce
potential bias and enhance the relationship between the variables.
The current study adds to the existing literature to help improve the health of
marijuana users by first, enhancing the care management of the drug users by
accelerating the medical diagnostic process, and secondly, by helping to improve liver
transplant denial policies for marijuana users.
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